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1. INTRODUCTION 
 
Stress is widely defined as a harmful factor (biological, chemical or physical), which 
triggers a series of cellular and systemic events, resulting in reparation of cellular and 
organismal homeostasis. Organisms have developed a broad range of stress response 
mechanisms to cope with stress conditions, acting at the cellular or organelle-specific level. 
The cellular stress response can be defined as a reaction to the threat of damage of the 
structure and function of macromolecules, including proteins, DNA, RNAs and lipids. It 
includes an evolutionarily highly conserved mechanism that protects cells from environmental 
stressors such as heat, ultraviolet (UV) light, heavy metals, oxidative and osmotic stress and 
infection of microbial pathogens. Cells can respond to different types of environmental stress 
in several ways ranging from activation of cell survival pathways to eliciting programmed cell 
death.  
The initial cell response to stressful conditions is the repairing of damaged 
macromolecules, helping the cell to defend against and recover from the insult serving thus to 
promote cell survival conditions. However, if the damage is too severe to be repaired, then 
cells activate stress signaling cascades to mediate cell death pathways [1]. Although the 
reactions of cells to environmental stress factors depend on the type and duration of the insult, 
cells respond rapidly and transiently to all types of stress by activation of four basic 
mechanisms, all of which are aimed at stabilizing macromolecular structures and functions 
[2]. The transient cellular stress responses are mediated through: 
(1) induction of cell cycle checkpoint control mechanisms leading to cell growth arrest – cell 
cycle checkpoints are triggered by genotoxic stress in eukaryotic cells such as the G1/S 
checkpoint [3], the G2/M checkpoint [4] and translational control mechanisms [5]; 
(2) induction of molecular chaperons, including the heat-shock proteins (Hsps), – Hsps are 
commonly activated either by induction [6] or by post-translational modification such as 
phosphorylation, i. e. Hsp27 is known to be activated by phosphorylation via the p38 MAP 
kinase signaling pathway [7]; 
(3) activation of mechanisms for nucleic acid stabilization and repair – for instance tumor 
protein 53 (p53) pathway [8] and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) pathway [9] are activated as part of the eukaryotic DNA damage response; 
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(4) clearance of damaged macromolecules generated by stress – in response to cellular stress 
signals including heat shock, oxidative damage or microbial infection, heat shock proteins, 
such as Hsp27 and Hsp90 have a significant role in increasing the activity of the 
ubiquitin/proteasome system to mediate the degradation of damaged proteins [10]. 
If the cellular stress responses fail to repair the damaged macromolecular structure 
caused by stress, then cell death pathways are activated. The most well-known cell death 
mechanisms involve apoptosis, pyroptosis, necrosis and in some circumstances autophagic 
cell death. Apoptosis, one type of noninflammatory programmed cell death is triggered 
through two different pathways, the intrinsic (mitochondria-mediated) pathway and the 
extrinsic (receptor-mediated) pathway [11]. Apoptosis is regulated by many proteins, such as 
caspases (cysteine-dependent aspartate-specific protease), B-cell lymphoma 2 (Bcl-2) -related 
proteins, and p53 [12]. Although several proteins contribute to the control of apoptosis, 
caspases are believed to be the most significant participants of this process. Activity of 
caspases lead to many of the morphologic features of apoptotic cell death, including 
membrane blebbing, polynucleosomal DNA fragmentation, nuclear shrinking and to the loss 
of overall cell shape [13, 14]. When apoptosis is inhibited, an alternative programmed cell 
death mechanism, the autophagic cell death is activated [15]. Autophagy (self-eating) is a 
multistep process characterized by the vesicular sequestration and degradation of unnecessary 
or dysfunctional cellular components through the lysosomal machinery [16]. Although the 
interplay between apoptosis and autophagy is poorly understood, several studies suggest that 
autophagy and apoptosis are antagonistic events that tend to inhibit each other [17, 18]. 
Necrosis, the additional type of cell death mechanisms has long been considered as an 
accidental and uncontrolled mode of cell death. Recently it has become clear that the 
execution of necrotic cell death is also molecularly regulated by a set of signaling pathways. 
These pathways are also associated with pathological conditions such as ischemia-reperfusion 
(IR) injury, neurodegeneration and pathogen infection [19-23]. For instance, tumor necrosis 
factor receptor 1 (TNFR1), and toll-like receptors (TLRs) have been reported to trigger 
necrosis [19] and the serine/threonine kinase receptor-interacting protein 1 and 3 (RIP1 and 
RIP3) have been described as key mediators of the initiation of necrosis induced by ligand-
receptor interactions [11, 24]. Necrosis is characterized by membrane rupture, nuclear 
swelling, and the release of cellular contents and is accompanied by caspase-independent 
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inflammation. Finally, pyroptosis is a form of inflammatory programmed cell death associated 
with antimicrobial responses during inflammation.  In contrast to apoptosis, pyroptotic cell 
death is coordinated by inflammasome-mediated caspase-1 activation and accompanied by 
membrane rupture, DNA fragmentation and the release of pro-inflammatory cytokines, 
including interleukin-1β and interleukin-18 (IL-1β and IL-18) [25]. 
Infection with microbial pathogens, such as viruses, bacteria, fungi, and protozoa 
elicits a diverse array of host protective and stress responses, including cell death and 
proliferative responses, inflammatory and innate immune responses. To sacrifice pathogen 
infected cells for the benefit of the remaining tissue is one of the main immune defense 
mechanisms of multicellular organisms [25]. For instance, in response to bacterial infection, 
programmed cell death, such as apoptosis, necrosis and pyroptosis are induced as a host 
innate immune response (Fig.1) [11]. During pathogen infection the innate immune system 
constitutes the first line of host defense and plays a crucial role in the early recognition and 
subsequent triggering of a pro-inflammatory response [26]. Human body surfaces are 
defended by epithelia, which provide a physical barrier between the internal milieu and the 
external world that contains pathogens.  Epithelial cells act as front-line defense executioners 
against microbial invasion by using pathogen recognition receptors (PRRs) including TLRs, 
NOD-like receptors (NLRs), retinoic acid-inducible gene (RIG-I) - like receptors (RLRs), 
retinoic acid inducible gene-I like RNA helicases (RLHs) and C-type lectin receptor to 
recognize pathogen-associated molecular patterns (PAMPs) and danger-associated molecular 
patterns (DAMPs) [27-29]. PAMPs are microbe-specific molecules including bacterial 
carbohydrates, i. e. lipopolysaccharide (LPS) and mannose, bacterial peptides, like flagellin, 
nucleic acids including bacterial DNA or viral RNA or DNA, bacterial peptidoglycans, 
lipoteichoic acids, lipopeptides, viral glycoproteins, like hemagglutinin and glycoprotein-41 
and fungal glucans which elicit immune response [30].  Following ligand recognition, PRRs 
present signal to the host and trigger proinflammatory and antimicrobial response by 
activating several intracellular signaling pathways, including kinases and transcription factors 
resulting the activation of gene expression and synthesis of a broad range of molecules, 
including cytokines, chemokines, cell adhesion molecules, and immunoreceptors [30]. All of 
these mechanisms build up the early host response to infection and at the same time represent 
an important link to the adaptive immune response. 
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Figure 1. Bacteria-induced host cell death. Bacteria induce host cell death through several distinct modalities, 
including apoptosis, necrosis, and pyroptosis [11]. 
 
 
The goal of our work was to investigate the epithelial cell stress responses following 
viral and bacterial infection using two model systems. 
First, we examined the role of two heparan sulfate proteoglycans, (HSPGs) syndecan-
1 and syndecan-2 in herpes simplex virus-1 (HSV-1) infection. Since syndecan-1 and 
syndecan-2 are relatively common HSPGs found on the target epithelial cells for HSV-1 
infection [31, 32] and previous studies have shown that several microbial pathogens can alter 
syndecan-1 expression [33-35] we aimed to explore the role of syncecan-1 and syndecan-2 
core proteins in HSV-1 infection. Using protein expression studies we tested whether HSV-1 
infection has an effect on syndecan-1 and syndecan-2 protein expression level in human 
cervical cell line (HeLa). Since studies have shown that heparan sulfate (HS) plays an 
important role in HSV-1 entry as an attachment receptor [36], the role of specific 
proteoglycan core proteins in the infection process remains poorly understood. Therefore we 
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performed in vitro studies using HeLa cells to determine the effect of syndecan-1 and 
syndecan-2 gene silencing on viral entry, plaque formation and cell survival using small 
interfering RNAs (siRNAs) specific for HSPGs.  
Second, our aim was to explore the role of Psoriasis Susceptibility Related RNA gene 
Induced by Stress (PRINS) in bacterial LPS induced cellular stress response in both 
immortalized HaCaT cells and in normal human keratinocytes (NHKs). We recently 
established that HaCaT cells and NHKs exhibit different PRINS expression patterns upon 
translation inhibition, UV-B and LPS induction and upon treatment with several microbial 
pathogens using quantitative real time RT-PCR methods [37, 38]. To identify whether this 
differential PRINS expression caused by the alteration of nuclear factor-κB (NF-κB) signal 
transduction pathway and whether PRINS was involved as an upstream regulator of it we 
silenced the PRINS gene expression with siRNAs in both HaCaT cells and in NHKs and 
monitored NF-κB signal transduction following LPS treatment.  
 
1.1 Herpes simplex virus type-1 and host cells interaction 
 
1.1.1 Herpes simplex viruses 
 
The Herpesviridae family forms a large and diverse group consisting over 100 double-
stranded DNA viruses of three subfamilies designated as Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae [36]. Herpes simplex viruses (HSV): type-1 
(HSV-1) and type-2 (HSV-2) are part of the Alphaherpesvirinae subfamily of Herpesviridae 
family. The herpes simplex virion consists of a linear, double-stranded DNA genome (152 
kb), packaged into an icosahedral capsid that consists of 162 capsomeres with six different 
viral proteins (VPs) present on the surface. The icosahedral capsid is surrounded by a layer of 
22 proteins called the tegument and a lipid bilayer envelope derived from the host cell 
membrane in which most cell proteins have been replaced by viral membrane proteins. The 
envelope is composed of 16 viral proteins, including 12 different glycoproteins (gB, gC, gD, 
gE, gG, gH, gI, gJ, gK, gL, gM, and gN) [39, 40] (Fig. 2). The protected DNA genome and 
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the coordinated action of at least four glycoproteins: D (gD), B (gB) and the heterodimer H 
(gH) and L (gL) were shown to be essential for viral infectivity [39].  
HSV occur worldwide and have no seasonal variation. Although HSV is normally 
isolated only from humans, many animal species can be experimentally infected, and many 
types and species of cultured cells support HSV replication [36, 41]. HSVs are neurotropic 
viruses producing a lifelong infection by establishing latency in the host sensory neurons of 
the peripheral nervous system and replicating in epithelial cells during primary infection and 
reactivation [42]. HSV cause a number of diseases ranging from oral and genital lesions to 
more severe conditions, such as herpetic stromal keratitis (HSK) a chronic inflammation of 
the cornea, the main non-traumatic cause of corneal blindness; meningitis and encephalitis 
[43-45]. The most common forms of disease caused by HSV are manifested as 
mucocutaneous lesions, which usually occur near the mouth (cold sores or fever blisters), on 
the cornea (keratitis), or on genital tissues. Oral and ocular lesions are primarily caused by 
HSV-1, while most genital HSV infections are caused by HSV-2; however, both strains have 
the ability to cause infection in either area of the body [36, 41]. Genital HSV-1 infections are 
usually less severe and less prone to recur than those caused by HSV-2 [41]. Less frequently, 
HSV can also cause life-threatening disease affecting vital organs, including encephalitis in 
apparently healthy adults, meningitis, myelitis, radiculitis and disseminated disease in infants. 
The viruses isolated from adult encephalitis cases, keratitis and facial lesions are usually 
HSV-1, whereas those isolated from cases of neonatal disease, adult meningitis and genital 
lesions are usually HSV-2 [36, 41]. Many demographic factors affect acquisition of HSV 
infection. In less developed countries, HSV-1 seroconversion happens early in life – at the age 
of 5 years in around one third of children, and in around 70–80% by adolescence. In 
comparison, middle-class and upper-class individuals in more developed countries become 
infected later on – seroconversion occurs in about 20% of children younger than 5 years; then 
no substantial rise in incidence happens until an increase to 40–60% at the age between 20 to 
40 years [41]. HSV-2 seroprevalence rises from about 20–30% at the age between 15 to 29 
years to 35–60% by age 60 years [46]. Since the virus that causes the primary lesions 
establishes latent infections in sensory or autonomic peripheral neurons and can be reactivated 
by appropriate stimuli, periodic recurrences of herpetic lesions are common and present one 
of the troublesome aspects of infections with HSV [36]. A wide variety of environmental 
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events can trigger the reactivation of the virus, including emotional or physical stress, 
hormonal changes, menstruation, fever, exposure to sunlight or ultraviolet (UV) light and 
tissue damage [41].   
 
 
 
 
 
Figure 2. Schematic representation of HSV structure [http://www.manufacturingchemist.com]. 
 
1.1.2 The entry of HSV-1 into host cells 
 
HSV-1 entry into host cells marks the first and possibly most critical step in viral 
pathogenesis that is a result of fusion between the viral envelope and the membrane of the 
host cell. This process is mediated by the action of five viral glycoproteins (gB, gC, gD, gH 
and gL) along with their interactions with their cognate receptors [47] (Fig. 3). However, only 
four of these glycoproteins, such as gB, gD, gH, and gL are necessary and sufficient to allow 
viral fusion with the host cell plasma membrane [48-50]. Although gC is dispensable for the 
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infection of cultured cells; either gC or gB can mediate the binding of HSV-1 to cells; gC 
presence can increase the efficiency of virus binding almost 10-fold [49, 51].  
 
 
 
 
 
Figure 3. HSV-1 glycoproteins required for viral entry and their identified receptors. HSV-1 entry requires 
the glycoproteins gB, gD, and the heterodimer gH-gL. Some of the receptors are exclusive to HSV-1 including 
PILRα and 3-OS HS [52].  
 
The initial contact of HSV-1 with the host cells is the binding of viral gC and/or gB to 
HS chains of proteoglycans on cell surface [53, 54]. Filopodia, the F-actin-rich membrane 
protrusions may facilitate the attachment by providing HSPG-rich sites for the initial binding. 
Although HSV-1 attachment to HS via gB and gC enhances the infection, it is not absolutely 
essential for viral entry [53, 54]. Viral attachment to the cell surface membrane is followed by 
virus penetration and entry of the nucleocapsid into the cytoplasm. Two major modes of 
HSV-1 entry exist: 1. a fusion of the virion envelope with the plasma membrane which is pH 
independent and 2. a generally pH dependent phagocytosis-like endocytosis where the virus 
triggers the fusion with the membrane of an intracellular vesicle plasma membrane of the host 
cell [55, 56] (Fig. 4). 
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Figure 4. HSV virion and its two major modes of entry into cells. Structural components of a typical HSV 
virion are shown. HSV virions can enter into cells via a pH-independent fusion of viral envelope with the plasma 
membrane (I) or, alternatively, via an endocytic pathway that may be phagocytosis-like (II) in terms of the viral 
uptake [57]. 
 
The specific mode of HSV-1 entry takes place in a cell type dependent manner. For 
example, HeLa and human retinal pigment epithelial cells (RPE) allow HSV-1 entry through 
pH-dependent endocytic pathway while in African green monkey kidney cells (Vero) HSV-1 
can penetrate via direct fusion with the plasma membrane at neutral pH [58-60]. Regardless of 
the entry route followed, HSV-1 enters host cells by inducing fusion between the viral 
envelope and the host cell membrane and this mechanisim requires essential participation of 
four viral glycoproteins gB, gD, gH and gL as well as cellular receptors for both gB and gC 
[61-63]. It has been shown previously that soluble form of gB is capable of binding to HSPG 
deficient cells, and block virus entry, suggesting the presence of a HS independent gB 
receptor [64]. Recently, three gB receptors have been identified: 1.) the paired 
immunoglobulin-like type 2 receptor-α (PILRα) [62], 2.) the myelin-associated glycoprotein 
(MAG) [63], which are both members of the paired receptor families, and 3.) the non-muscle 
myosin heavy chain IIA (NMHC-IIA), a subunit of non-muscle myosin IIA [65]. While 
PILRα and MAG expressions are limited to immune and glial cells, respectively, NMHC-IIA 
 17 
is ubiquitously expressed in numerous human tissues and cell types, suggesting its important 
role as the functional HSV-1 gB receptor [52, 65]. Following gC and/or gB interaction with 
the cell surface, viral entry requires the interaction of gD with one of its entry receptors. 
These receptors are: nectin-1 (HveC) and nectin-2 (HveB), which are both members of the 
immunoglobulin superfamily [66], herpesvirus entry mediator (HVEM) that belongs to the 
tumour necrosis factor receptor family [67], and 3-O-sulfated heparan sulfate (3-OS HS) a 
specifically modified form of HS [68, 69]. Upon binding of gD to one of its cognate receptors, 
gD undergoes conformational change, which may transmit an activation signal to gB, and 
gH/gL leading to membrane fusion. Thus, HSV-1 require essential participation of viral 
glycoproteins gB, gD, gH and gL which form a multi-glycoprotein complex (fusogenic 
complex) to execute fusion [56, 70]. Fusion of viral envelope with the cellular membrane 
results in the release of the naked viral nucleocapsid into the host cytoplasm for transport to 
the nucleus. HSV-1 has evolved to use multiple receptors and pathways to facilitate entry into 
different cell types. This differential use of cell membrane receptors is important, and may 
help in productively infect a wide range of hosts and cell types [71, 72].  
 
1.1.3 Heparan sulfate proteoglycans (HSPGs) 
 
HS is a glycosaminoglycan (GAG) that is present in almost all mammalian tissues on 
cell surfaces and in the extracellular matrix [73, 74]. HS commonly occurs as part of 
proteoglycans, where HS GAG chains are attached to a core protein via a trisaccharide 
linkage on a serine residue forming the HSPG [75]. The syndecan family is one of the most 
abundant HSPGs expressed on mammalian cells [76-78]. There are four members in the 
syndecan family (syndecan-1, 2, 3 and 4) composed of a single membrane-spanning domain, 
a conserved transmembrane domain, and an extracellular domain that is specific for each 
syndecan ([79]. The divergent ectodomains share conserved attachment sites for GAG chains. 
These GAGs are predominantly heparan sulfated [80, 81] but syndecan-1 and syndecan-4 can 
also contain chondroitin sulfate (CS) in addition to HS [82, 83]. HSV-1 commonly infects 
epithelial cells, which express both syndecan-1 and syndecan-2 [84, 85]. In addition, 
syndecan-1 (CD138, NCBI Reference Sequence: NP_001006947) is also expressed by many 
other cell types including plasma cells. In contrast, syndecan-2 (fibroglycan, NCBI Reference 
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Sequence: NP_002989) shows a more restricted expression pattern, limited mainly to 
fibroblasts and neurons [86-88].  
 
1.2 The role of PRINS non-coding RNA in psoriasis and cellular stress response 
 
1.2.1 Psoriasis  
 
Psoriasis is a frequent, chronic, lifelong inflammatory skin disease, generally 
characterized by complex alterations in epidermal growth and differentiation. 
Hyperproliferation of the epidermal cells is believed to be triggered by infiltrating T-
lymphocytes at the dermal epidermal junction [89] and by the accumulation of various 
cytokines and inflammatory mediators which directly modulate keratinocyte proliferation and 
differentiation [90]. Clinically, psoriasis is a papulosquamous disease with variable 
morphology, distribution and severity that is characterized by red plaques (due to dilation of 
blood vessels; raised lesions 1 cm in diameter) with silver or white scales (due to rapid 
keratinocyte proliferation; raised lesions 1 cm in diameter) that are clearly distinguished 
from adjacent, normal appearing, non-lesional skin [91]. The morphology of psoriasis can 
range from small tear shaped papules (guttate psoriasis) to pustules (pustular psoriasis) and 
generalised erythema and scale (erythrodermic psoriasis). Almost 90% of psoriasis patients  
have the most common form of the disease, known as psoriasis vulgaris and many affected 
individuals have a mild form but up to one third of patients have moderate-to-severe form of 
psoriasis affecting more than 10% of the body surface [92]. Even though cutaneous signs and 
symptoms are the most common clinical manifestations, nails are frequently affected in up to 
50% of cases [93] and approximately 30 % of patients with psoriasis also have joint 
involvement, indicative psoriatic arthritis [94, 95]. Depending on the severity of disease, 
psoriasis can be treated with topical agents, ultraviolet light therapy and systemic medications 
[96].  
The exact couse and progress of psoriasis remains poorly understood but it is believed 
that the combination of genetic and environmental factors contributes to the development of 
this complex disease [94, 96] and the immune system and its interactive network of 
leukocytes and cytokines play important role in psoriasis pathogenesis [97, 98]. 
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Environmental causes of psoriasis may include mechanical, ultraviolet and chemical injury of 
the skin, various infections, prescription drug use, psychological stress and smoking [99-102]. 
Several studies have revealed that one of the most frequent environmental factors triggering 
psoriasis is the upper respiratory tract infection caused by β-haemolytic streptococci [103, 
104]. Streptococcal infection of the pharynx or tonsils frequently precedes outbreaks of 
guttate psoriasis in children or, occasionally, adults [105]. According to several studies, 
psoriasis may not be restricted to the skin; evidence is now emerging of a link between 
psoriasis and other diseases such as inflammatory bowel diseases (Crohn’s disease, colitis 
ulcerosa) [106], ocular inflammatory diseases (uveitis, iritis) [107], chronic vascular and 
metabolic disorders (arterial hypertension, hyperlipidemia, diabetes mellitus type II and 
coronary heart disease) [108], depression, cigarette smoking and heavy consumption of 
alcohol [109-112].  
Family based analyses of patients with psoriasis, especially twin studies; population 
based epidemiological studies and genome-wide association studies (GWAS) have revealed 
the strong genetic basis of psoriasis [113-116]. Nine susceptibility loci for psoriasis have been 
identified using classic GWAS and referred to as, psoriasis susceptibility 1 through 9 
(PSORS1 on 6p21.3, PSORS2 on 17q25, PSORS3 on 4q34, PSORS4 on 1q21, PSORS5 on 
3q21, PSORS6 on 19p13, PSORS7 on 1p32, PSORS 8 on 16q and PSORS9 on 4q31[117-
119]. Altought recent studies have confirmed further susceptibility loci [120-128], the 
PSORS1 locus is the major susceptibility locus for psoriasis which accounts for 
approximately 35% - 50% of the genetic risk for this disease [129-131]. 
Considerable effort has been devoted to identifying genetic factors and biochemical 
alterations in the epidermis which contribute to the pathogenesis of psoriasis and resulted in 
the discovery of psoriasis susceptibility loci, a large number of psoriasis-associated genes and 
aberrantly expressed genes and proteins in the recent decades [125, 132, 133]. A number of 
gene expression profiling methods like serial analysis of gene expression (SAGE) and 
microarray analyses have been used in studies to characterize transcriptional changes in 
psoriasis and identificate large number of novel disease markers [134-139]. These studies 
were performed on skin biopsies of involved and non-involved, normal appearing psoriatic 
skin and normal skin from patients with active psorasis and from healthy individuals, 
respectively. Previous studies have shown that the gene expression pattern of lesional 
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psoriatic skin is significantly different from normal skin of unaffected individuals [117, 134, 
140]. Additionally, the transition from non-involved into involved psoriatic skin is 
accompanied by changes in the expression of multiple genes [139]. Some of the earliest 
identified genes as having significant over-expression in involved psoriatic skin include 
transforming growth factor-α (TGF-α) [141], tumor necrosis factor-α (TNF-α) [142], vascular 
endothelial growth factor (VEGF) and its receptors [143] and proteinase inhibitors such as 
peptidase inhibitor 3 (SKALP) [144]. Whereas previous investigations have focused only on 
the expression of small number of genes [145], recently more comprehensive analyses such as 
Affymetrix oligonucleotide arrays are used to characterize changes in gene expression of 
psoriasis [134-136, 139]. Among others, Zhou et al., Romanowska et al. and Gudjonsson et al. 
have identified a wide range of dysregulated genes in lesional and non-lesional psoriatic skin 
samples compared with normal skin samples using microarray analyses [136, 139, 140].  
Taken together, these microarray studies have identified a number of candidates 
suggested in original candidate studies as well as novel genes not previously implicated in the 
pathogenesis of psoriasis. These candidate genes are involved in well-established aspects of 
psoriasis, such as keratinocyte differentiation, interferon signaling or influx of inflammatory 
cells and wide range of biological processes are connected with pathogenesis of psoriasis 
[136, 137]. For istance, fatty acid metabolism; protein trafficking and degradation; cell 
adhesion; signaling transduction; mitogen-activated responses; RNA binding, regulation and 
degradation; cytoskeleton restructuring and apoptosis have been correlated with the 
pathogenesis of psoriasis using microarray analyses [136, 137]. 
 
1.2.2 Non-coding RNAs 
 
As our understanding of the complex function of the human genome has advanced, a 
great role has been ascribed to the enormous part of the genome that does not code proteins. 
Non-coding RNAs (ncRNAs) have recently been at the centre of attention as a large and 
diverse group of molecules responsible for a growing list of cellular regulatory functions, 
such as transcriptional regulation, chromosome replication, RNA processing and 
modification, messenger RNA (mRNA) stability and translation, protein degradation and 
translocation [146, 147]. Investigation of the role of ncRNAs in physiological and 
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pathological mechanisms is therefore of great importance as concerns the elucidation of the 
complex regulatory pathways involved in human development and disease formation [147].  
We earlier performed a differential display experiment to compare the gene expression 
in the non-lesional psoriatic epidermis and the epidermis from healthy individuals, in order to 
identify molecular psoriasis susceptibility factors [37]. In that experiment, we identified a 
novel ncRNA, PRINS which was overexpressed in the non-lesional psoriatic epidermis, and 
responded with an elevated expression after 12-24 h to various stress signals, including serum 
starvation, contact inhibition, UV-B irradiation, viral infection (HSV-1) and translational 
inhibition by cycloheximide in a series of in vitro experiments on HaCaT cells [37].  
These data indicated that PRINS might play a role in the cellular stress response 
induced by epidermal stress factors [37]. Knocking down PRINS expression in HaCaT cells 
by using a vector-based RNA interference method, did not have any impact on the control 
cells, whereas it decreased the viability of serum-starved keratinocytes, indicating its essential 
role in the survival of keratinocytes under stress conditions [37]. Furthermore, we have 
demonstrated that PRINS regulates G1P3, a gene with anti-apoptotic effects in keratinocytes. 
Our data indicated that the elevated level of PRINS ncRNA in the psoriatic epidermis may 
contribute to psoriasis by disrupting signal transduction events mediating genes involved in 
apoptosis regulation such as G1P3 [148].  
 
1.2.3 Nuclear factor-kappaB 
 
NF-κB is a widely studied transcription factor that regulates gene expression in a 
broad range of cellular processes. The NF-κB system has been shown to play a crucial role in 
epidermal development and differentiation, stress and immune responses, apoptosis, chronic 
inflammatory diseases and cancer [149, 150]. It is found in most mammalian cells, and is 
involved in cellular responses to stimuli of stress such as cytokines, free radicals, UV 
irradiation, oxidized low-density lipoproteins and bacterial or viral antigens. Within the 
stratified epidermis, NF-κB is located in the cytoplasm of the proliferative basal layer cells 
and while keratinocytes are differentiating it shifts to the nucleus in the non-proliferating 
suprabasal cells [151]. While the molecular mechanisms controlling this process have not 
been completely identified, change in cellular localization suggests a role for NF-κB in the 
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progression of keratinocytes from proliferation to growth arrest in the epidermis [151]. 
Additionally, several in vivo studies have suggested a key regulatory role of the NF-κB 
cascade in growth inhibition control during the process of differentiation of epidermal cells 
[151, 152]. Currently, five members of the NF-κB/Rel protein family are known: p50/p105, 
p52/100, c-Rel, p65/RelA and RelB [153]. In the resting state, the dimers are found in the 
cytoplasm, bound to the inhibitor κB (IκB). Upon stimulation, IκB is phosphorylated by the 
IκB kinase complex (consisting of IKKα, IKKβ and IKKγ (NEMO)) and subsequently 
degraded, allowing NF-κB to shift to the nucleus, where it can bind to transcription-regulating 
elements in a nucleotide sequence-specific manner to activate its target genes [154]. 
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2. AIMS 
 
2.1 To investigate the role of syndecan-1 and syndecan-2 in herpes simplex virus type-1 
infection 
 
 
• To examine the impact of HSV-1 infection on syndecan-1 and syndecan-2 protein 
synthesis and heparan sulfate expression on the human epithelial surface 
 
• To investigate the effect of syndecan-1 and syndecan-2 gene silencing by RNA 
interference on HSV-1 entry, plaque formation and cell survival in human epithelial 
cells 
 
 
2.2 To monitor whether PRINS is involved as an upstream regulator in the regulation of the 
NF-κB signal transduction pathway in normal human keratinocytes and in the immortalized 
keratinocyte cell line, HaCaT 
 
 
• To explore whether the silencing of PRINS expression has an effect on the LPS-
induced NF-κB response either in HaCaT cells or in NHKs  
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3. MATERIAL AND METHODS 
 
3.1 Cell lines 
 
Human cervical (HeLa) cells were obtained from B. P. Prabhakar (University of 
Illinois at Chicago, Chicago, IL, USA). HeLa cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco-BRL) supplemented with 10% fetal bovine serum (FBS) and 
100 mg of penicillin/streptomycin (P/S). African green monkey kidney cells (Vero), gL-
expressing Vero cells (79B4) and Chinese hamster ovarian-K1 (CHO-K1) cells were provided 
by P. G. Spear (North-Western University, Chicago, IL, USA). Vero and gL-expressing Vero 
cells (79B4) were grown in DMEM (Gibco-BRL) supplemented with 10% FBS and 100  
mg l-1 of P/S. CHO-K1 cells were grown in Ham’s F-12 medium (Gibco-BRL) supplemented 
with 10% FBS and P/S. The spontaneously immortalized non-tumorgenic human 
keratinocytes-derived cell line, HaCaT, kindly provided by Dr. N. E. Fusenig (German Cancer 
Research Center, Heidelberg, Germany), was cultured in a high-gulcose DMEM (Gibco-BRL) 
supplemented with 10% FBS, L-glutamine, antibiotics (P/S) and an antimycotic 
(amphoterecin B; Sigma). HaCaT cells previously stably transformed with an NF-κB 
responsive element - luciferase reporter gene chimeric construct (NF-κB-HaCaT), kindly 
provided by Zsuzsanna Györfy (Institute of Biochemistry, Biological Research Center, 
Hungarian Academy of Sciences, Szeged, Hungary) were cultured in DMEM/F12 1:1 
medium (Life Technologies) supplemented with 10% FBS, L-glutamine and 1% antibiotics 
(P/S) and an antimycotic solution (amphoterecin B, Sigma - Aldrich). NHKs were isolated 
from the healthy skin of patients who underwent plastic surgery, using standard protocols, and 
cultured in keratinocytes serum-free medium (Keratinocyte-SFM; Gibco-BRL) supplemented 
with antibiotics (P/S) and an antimycotic (amphoterecin B) solution. The medium was 
changed every 2 days. In our experiments, third-passage NHKs were used at 80% confluence. 
The study was approved by the Institutional Review Board of the University of Szeged and 
was performed in adherence to the Declaration of Helsinki Guidelines. Written informed 
consent was obtained from each patients involved in the study. The approval number form the 
local ethics committee: Human Investigation Review Board of the University of Szeged, Ref. 
No.: 2084 issued in April 24, 2006. 
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3.2 Viruses 
 
The β-galactosidase expressing recombinant HSV-1 (KOS) gL86 and wild-type HSV-
1(KOS) viruses were provided by P. G. Spear (North-Western University, Chicago, IL, USA). 
HSV-1 (KOS) K26GFP was provided by P. Desai (Johns Hopkins University, Baltimore, 
MD, USA). Jellyfish GFP was fused in-frame with the UL35 ORF generating the K26GFP 
virus whose capsids express GFP [155]. Virus stocks were propagated in complementing cell 
lines and stored at –80 ºC. Yields of infectious virus titer (p.f.u. ml–1) were determined by 
plaque assay in Vero cells. 
 
3.3 Antibodies  
 
 
Primary antibodies 
 Dilutions Resources 
mouse anti-syndecan-1 mAbs 1 µg per 1x106 cells Santa Cruz Biotechnology 
rat anti-syndecan-2 mAbs 1.25 µg per 1x106 cells R&D Systems 
mouse anti-heparan sulfate mAb (10E4 epitope) 1:50 US Biological 
rabbit anti-syndecan-1 pAb 1:500 Santa Cruz Biotechnology 
rabbit anti-syndecan-2 pAb 1:500 Santa Cruz Biotechnology 
mouse anti-β-actin mAb 1:1000 Sigma-Aldrich 
mouse anti-myc mAb 1:500 Life Technologies 
Secondary antibodies used for flow cytometry 
FITC-conjugated goat anti-mouse secondary antibody 1:100 Sigma-Aldrich 
FITC-conjugated goat anti-rat secondary antibody 1:100 Sigma-Aldrich 
FITC-conjugated goat anti-mouse IgM 1:100 Sigma-Aldrich 
Secondary antibodies used for Western blot 
HRP-conjugated goat anti-rabbit IgG 1:20000 Jackson ImmunoResearch Laboratories 
HRP-conjugated rabbit anti-mouse IgG 1:25000 Jackson ImmunoResearch Laboratories 
 
Table 1. Antibodies used for flow cytometry and Western blot 
 
3.4 Enzymes 
 
Heparinase I, II and III enzymes were provided by Jian Liu (University of North Carolina, 
Chapel Hill, NC, USA) and used at 12 µg per sample (170 µg ml–1 final concentration). 
Chondroitinase ABC was used at 0.005 U per sample (0.1 U ml–1 final concentration; Sigma-
Aldrich). 
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3.5 siRNA transfection  
 
HeLa and CHO-K1 cells were transfected at 80% confluence at a concentration of 200 
nM per well with syndecan-1 siRNA (59-CCAUUCUGACUCGGUUUCU[dT][dT]-39, and 
59-GCCAAGGUUUUAUAAGGCU[dT][dT]-39; Sigma-Aldrich), syndecan-2 siRNA 
(SASI_Hs01_00195372, SASI_Hs01_00195365; Sigma-Aldrich), or a non-specific, 
scrambled control siRNA (59-GAUCAUACGUGCGAUCAGA[dT][dT]-39; Sigma-Aldrich). 
Transfection was done by using Lipofectamine 2000 reagent (Life Technologies). To evaluate 
the efficacy of syndecan-1 and syndecan-2 gene silencing, Western blot analysis of syndecan-
1 and syndecan-2 protein expression was performed in a sample of HeLa cells that were mock 
treated (no transfection) or treated with scrambled siRNA, syndecan-1 siRNA or syndecan-2 
siRNA. Transfection efficacy was measured by using a plasmid encoding enhanced GFP 
(eGFP; Life Technologies) by counting eGFP-positive cells by fluorescence microscopy.  
 
3.6 Plasmid transfection 
 
The plasmids used in the detection of LPS-induced NF-κB activity experiment were 
pNF-κB-Luc (Stratagene), pGL4.75[hRluc/CMV] (Promega), pSilencer 2.1-U6 hygro 
(Ambion) and pmaxGFP (Lonza). To knock down PRINS expression, transient transfection 
experiments using a vector-based RNA interference method [37] were carried out both with 
the HaCaT cell line stably transformed with the NF-κB-luciferase chimeric construct and with 
NHKs. Both cell lines were transfected at 80% confluence with 2 µg/well plasmid DNA. 
Transient transfections were carried out with a Nucleofector device (Lonza) using the 
appropriate transfection reagents provided for HaCaT cells and NHKs. NF-κB-HaCaT cells 
were transfected with the PRINS silencing pSilencer 2.1-U6 construct (AK696) and a 
construct harboring a scrambled sequence of PRINS gene (SC1313), was used as a control. 
Third passage NHKs were simultaneously co-transfected with the NF-κB-luc plasmid and 
either with the PRINS silencing pSilencer 2.1-U6 construct (AK696) or with control construct 
(SC1313). To evaluate the efficiency of PRINS gene silencing, the PRINS RNA level was 
determined by quantitative real time PCR analysis in transfected NF-κB-HaCaT cells and 
NHKs. Transfection efficiencies in both NF-κB-HaCaT cells and NHKs were determined 
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after transfection of plasmid encoding the enhanced green fluorescent protein eGFP 
(pmaxGFP), using a dual-laser FACS-Calibur flow cytometer (Beckton Dickinson), and 
analyzed with the CellQuest Software.  
 
3.7 Viral entry assay 
 
Standard entry assay was used as described previously [68]. Briefly, HeLa cells and 
HSV-1 entry receptor defficient CHO-K1 cells were plated in 96-well tissue culture dish at a 
density of 8 x 103 cells per well. Cells were transfected with syndecan-1, syndecan-2 or 
scrambled siRNA as described above. After 48 h, cells were infected with the β-galactosidase 
expressing recombinant HSV-1(KOS) gL86 in a twofold serial dilution for 6 h at 37 ºC. β-
galactosidase expression is driven by HSV-1 ICP4 promoter by early viral protein synthesis 
upon HSV infection [67, 68]. At 6 h post-infection, cells were washed twice with PBS and the 
soluble substrate O-nitrophenyl-b-D-galactopyranoside (ONPG; Pierce) was added. Enzymic 
activity was measured at 410 nm using a micro-plate reader (Spectra Max 190 Molecular 
Devices).  
 
3.8 Antibody blocking assay 
 
Standard antibody blocking assay was used as described previously [156]. Briefly, 
confluent HeLa cells in 96-well tissue culture dish were washed with PBS and incubated with 
serial dilutions of rabbit pAbs to sydecan-1, syndecan-2 (Santa Cruz Biotechnology) or 
control anti-myc mAb (Life Technologies) for 30 min at 37 ºC. A constant dose of HSV-
1(KOS) gL86 (m.o.i. of 10) was then added to all wells for 2 h at 37 ºC. After 2 h, cells were 
washed and the bound viruses were removed by a 20 s treatment with 100 mM citrate buffer 
(pH 3.0). Incubation was then continued for another 3 h. Cells were then washed twice with 
PBS and β-galactosidase activity was measured by adding its substrate ONPG as described in 
virus entry assay. 
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3.9 Plaque assay  
 
Viral replication upon syndecan-1 and syndecan-2 knockdown was assessed by plaque 
assay [157]. In brief, monolayers of HeLa cells plated in six-well tissue culture dishes were 
transfected with syndecan-1, syndecan-2 or scrambled siRNA as described above. At 48 h 
post-transfection, cells were infected (m.o.i. of 0.01) with HSV-1 (KOS) or mock infected in 
PBS for 90 min at 37 ºC. Cells were then washed with PBS and fresh medium (DMEM 
supplemented with 10% FBS and P/S) was added. Cells were incubated for 72 h at 37 ºC. 
After 72 h, cells were washed with PBS, fixed with 100% methanol for 5 min, and stained 
with the Giemsa stain (Sigma-Aldrich) for 20 min. Infectivity was assessed by counting 
plaques formed using a 10x objective lens of an inverted light microscope (Zeiss Axiovert 
200). 
 
3.10 Cytotoxicity assay  
 
Confluent monolayer of HeLa cells were transfected with syndecan-1, syndecan-2 or 
scrambled siRNA as described above. In addition to the non-specific, scrambled siRNA 
transfected cells, non-transfected cells were also used as controls. Forty-eight hours post-
transfection, cells were infected with HSV-1(KOS) (m.o.i. of 0.01) for 90 min at 37 ºC. The 
inoculum was then removed by washing the cells with PBS and fresh medium was added. 
Cells were incubated at 37 ºC for 120 h, then fixed with 100% methanol and stained with 
Giemsa stain. The number of dead cells was determined using NIH Image J software (version: 
1.43) at twenty high power fields (x 40 objective). 
 
3.11 Flow cytometry 
 
Syndecan-1 and syndecan-2 and HS cell surface expression was detected after HSV-
1(KOS) infection. For syndecan-1 and syndecan-2 cell surface expression, confluent 
monolayers of HeLa cells were infected with HSV-1 (KOS) (m.o.i. of 10) for 0, 2, 4 and 6 h. 
Cells were then washed with PBS, harvested and incubated with the respective primary 
antibody (syndecan-1 at 1 µg per 1x106 cells, or syndecan-2 at 1.25 µg per 1x106 cells) 
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diluted in PBS with 1% BSA for 1 h. After primary antibody incubation, cells were washed 
and incubated for 45 min with anti-mouse or anti-rat-FITC-conjugated secondary anti-IgGs 
(1:100). Cells stained only with anti-mouse-FITC or anti-rat-FITC were used as background 
controls. For HS cell surface expression, HeLa cells were infected with HSV-1 (KOS) (m.o.i. 
of 10) for 0, 2, 4 and 6 h. Cells were then washed with PBS, harvested and incubated with 
mouse anti-human HS mAb 10E4 diluted 1:50 (US Biological) for 20 min at 4 ºC. After that 
the cells were washed and incubated for 30 min at 4 ºC with FITC-conjugated anti-mouse 
IgM diluted to 1:100. Cells stained only with FITC-conjugated anti-mouse IgM were used as 
background controls. Transfection efficiencies in NF-κB-HaCaT cells and NHKs were 
determined after transfection of 2 µg/well of pmaxGFP, using a dual-laser FACS-Calibur flow 
cytometer (Beckton Dickinson) and analyzed with the CellQuest Software. 
 
3.12 Immunoblotting 
 
After 48 h post-transfection of HeLa cells and 0, 2 and 6 h after HSV-1(KOS) 
infection (m.o.i. of 10), syndecan-1 and syndecan-2 protein expression was determined by 
Western blot analysis. The Western blot assay was performed according to the protocol 
described previously [158]. Briefly, approximately 150–200 µg of total cell protein in lysis 
buffer was incubated with 2.5 volumes of –20 ºC 100% methanol overnight at –20 ºC. After 
treatment with 500 µl 100% acetone for 5 min, the protein pellet was redissolved in 100 µl 
heparinase buffer (0.1 M NaOAc+0.1 mM CaOAc, pH 7.0). GAGs were digested with 
heparinase I, II, III (12 µg per sample) and chondroitinase ABC (0.005 U per sample) twice 
for 2.5 h to remove all GAGs. Samples were then denatured in Laemmli Sample Buffer (Bio-
Rad) with 5% (v/v) β-mercaptoethanol and heated to 96 ºC for 10 min before loading onto a 
SDS-PAGE gel. Separated proteins were then transferred to nitrocellulose membrane, blocked 
for 2 h at room temperature in 0.1% TTBS (0.1% Tween 20 in TBS) containing 5% milk, and 
incubated with primary rabbit pAbs against sydecan-1 and syndecan-2 at 1:500 dilutions 
overnight at 4 ºC. The blots were rinsed five times with 0.1% TTBS for 5 min and incubated 
for 1 h at room temperature with HRP-conjugated anti-rabbit IgG at 1:20000 dilutions. Anti-
β-actin mouse mAb as the primary antibody at 1:1000 dilution and HRP-conjugated anti-
mouse IgG as the secondary antibody at 1:25000 dilution were used for detecting β-actin as a 
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loading control. The signal was visualized with SuperSignal West Femto maximum 
sensitivity substrate (Pierce) and the blots were exposed to X-ray film (Kodak) for 2 min. 
Developed films were scanned and protein bands were quantified using the NIH Image J 
software (version: 1.42) in order to generate statistical data for specific bands. Syndecan-1 
and syndecan-2 protein expression was quantified by calculating the relative intensity of each 
syndecan-1 and syndecan-2 band relative to the bands of mock-treated cells. 
 
3.13 Detection of LPS-induced NF-κB activity 
 
Luciferase assays were performed to determine the NF-κB activity in response to LPS 
(purified from Escherichia coli; Sigma-Aldrich) stimulation of the NF-κB-HaCaT cells and 
NHKs. To assay the effect of LPS induction on NF-κB promoter activity, NF-κB-HaCaT cells 
(HaCaT cells previously stably transformed with the NF-nB/luc/neo reporter plasmid, [159]) 
were transfected with the PRINS silencing construct and NHKs were co-transfected with NF-
κB-luc plasmid, pGL4.75 [hRluc/CMV] plasmid and pSilencer 2.1-U6 plasmid construct. 24 
h after transfection, cells were incubated with 2.5 µg/ml LPS for 4 h. The treated cells were 
washed twice with PBS and lysed with passive lysis buffer (Promega) and the luciferase 
activities in the lysates were measured with the Promega Luciferase Assay System according 
to the manufacturer’s instructions (Promega). Firefly and Renilla luciferase activities were 
measured in a Thermo Luminoskan Ascent Machine (Thermo Scientific). For the 
standardization of transfection efficiency in NHKs, the luciferase activity derived from pNF-
κB-Luc was normalized to the activity of Renilla luciferase. The protein concentrations of 
NF-κB-HaCaT cell lysates were determined by using the Bradford protein assay. Transient 
transfection efficacy was detected with positive control vector pmaxGFP by FACS analysis. 
The efficacy of PRINS silencing was detected by using real-time RT-PCR for each 
experiment. Results were confirmed by at least three independent transfections. 
 
3.14 Real-time reverse transcriptase PCR 
 
For real time reverse transcriptase PCR (RT-PCR), 1 µg of purified total RNA was 
reverse transcribed by using the iScript kit (Bio-Rad). After reverse transcription, real time 
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RT-PCR was performed to quantify the abundance of PRINS RNA. PRINS RNA expression 
data were normalized to the 18S ribosomal RNA expression data of each examined sample. 
TaqMan probes were purchased from IDT Probes. The RT-PCR reactions were performed 
with the iQ Supermix (Bio-Rad) in an iCycler (Bio-Rad). The primer sets and TaqMan probes 
used for the reactions are listed in Table 2. 
 
 
 Forward primer Reverse primer Probe 
PRINS GCATCTTCCCTTGGCAAA GCCTAAAGGACATTTCGGTAT TGC TGT TTT GGG TCC TAA CCA TC 
18S CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT TGC TGG CAC CAG ACT TGC CCT C 
 
Table 2. Sequence of primers and probes used for RT-PCR. 
 
3.15 Statistical analyses 
 
Statistical analyses were performed with the STATISTICA software (version 8.0) for 
windows. Normality was tested using the Kolmogorov–Smirnov test. All variables were 
distributed normally. Homogeneity of variance was determined using Levene’s test and was 
considered violated when this test yielded p<0.05. All variances were homogeneous. Data 
were assessed using ANOVA followed by Scheffe’s post-hoc test to evaluate the effects of 
gene silencing of syndecan-1 and syndecan-2 on HSV-1 viral entry, plaque formation and 
cytotoxicity. *p<0.05 and **p<0.0001 were regarded as significant differences between 
treated and mock-treated groups. The results are expressed as means ± SD values; each 
experiment was repeated at least three times. 
To evaluate the effects of silencing of PRINS on LPS-induced NF-κB activity data were 
assessed using the repeated measures ANOVA. *p < 0.05 was regarded as significant 
differences between treated and mock-treated groups. The results are expressed as mean ± 
(SE) values; each experiment was repeated at least three times. 
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4. RESULTS 
 
4.1 HSV-1 infection in HeLa cells enhances syndecan-1 and syndecan-2 cell surface 
expression 
 
Earlier reports have established that infection with microbial pathogens can result in 
significant changes in syndecan expression [33-35, 160]. To determine whether HSV-1 
infection affects cell surface expression of syndecan-1 and syndecan-2, the expression level of 
syndecan-1 and syndecan-2 on HeLa cell surface was analyzed at various times after HSV-
1(KOS) infection by flow cytometry. Cell surface expression levels of syndecan-1 and 
syndecan-2 in mock-infected HeLa cells were used as controls. As shown in Figure 5., both 
syndecan-1 and syndecan-2 cell surface expressions were significantly upregulated as soon as 
2 h after HSV-1 infection. The increases were also observed at 4 and 6 h post-infection in 
HeLa cells. 
 
 
 
 
 
Figure 5. HSV-1 infection of host cell enhances syndecan-1 and syndecan-2 cell surface expression in HeLa 
cells. Cells were infected with a constant dose of HSV-1 (KOS) (m.o.i. of 10) for 2, 4 or 6 h. Syndecan-1 and 
syndecan-2 cell surface expression was then detected by FACS analysis. Enhanced syndecan-1 (a) and syndecan-
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2 (b) cell surface expression was detected in HeLa cells following HSV-1 infection. Mock-infected FITC stained 
cells were used as background control. Results are representative of three independent experiments. 
 
4.2 HSV-1 infection in HeLa cells enhances syndecan-1 and syndecan-2 protein synthesis 
 
Since HSV-1 infection enhances syndecan-1 and syndecan-2 cell surface expression, 
this enhancement could be a result of protein synthesis induction or a higher redistribution of 
HSPGs on the cell surface. To determine if HSV-1 infection modulates syndecan-1 and 
syndecan-2 expression at the protein level, Western blot analysis was performed on HeLa 
cells. Mock-infected cells were used as controls. Densitometric analysis showed that the 
expression level of syndecan-1 protein was increased by 1.64 ± 0.16-fold at 2 h and 2.01 ± 
0.16-fold at 6 h after HSV-1 infection (Fig. 6a). Syndecan-2 protein expression level was also 
increased by 2.59 ± 0.64-fold at 2 h and 3.16 ± 1.02-fold at 6 h after HSV-1 infection (Fig. 
6b). These results demonstrate that HSV-1 not only enhances the cell surface distribution of 
syndecans, but also induces de novo syndecan-1 and syndecan-2 protein synthesis. 
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Figure 6. Western blot analysis of syndecan-1 and syndecan-2 protein expression after HSV-1 (KOS) 
infection. HeLa cells were infected with a constant dose of HSV-1 (KOS) (m.o.i. of 10) for 2 and 6 h. Cell 
lysates were then probed for syndecan-1 and syndecan-2 expression. According to the densitometric analysis, 
syndecan-1 (a) and syndecan-2 (b) were expressed at a higher level at 2 and 6 h post-infection when compared to 
uninfected HeLa cells. Relative intensity of HSV-1(KOS) virus-infected bands expressed as a ratio relative to the 
mock-infected sample is shown. β-actin protein expression was measured as loading control. (means ± SD from 
three independent experiments). 
 
4.3 HSV-1 infection causes an increase of HS expression on cell surface 
 
Since HSV-1 infection of host cells results in an upregulation of protein expression 
and cell surface deposition of syndecans, we aimed to determine whether this may lead to an 
upregulation of HS as well. To investigate if HSV-1 infection affects HS cell surface 
expression, flow cytometry analysis was performed. At 2 h post-infection, HS surface 
expression increased in cells treated with HSV-1(KOS) compared to those that were mock 
treated (Fig. 7). However, at later time points, the increase of HS surface expression exhibited 
a plateau and did not show the dynamic increase we observed for syndecan-1 and syndecan-2 
upregulation after HSV-1 treatment.  
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Figure 7. Flow cytometry analysis of HS expression on HeLa cells infected with HSV-1. HeLa cells were 
infected with HSV-1(KOS) (m.o.i. of 10) for 2, 4 or 6 h. HS cell surface expression was then detected by FACS 
analysis. In HSV-1-infected cells, HS cell surface expression was enhanced compared with uninfected cells. 
Untreated FITC-stained HeLa cells were used as background control. Results are representative of three 
independent experiments. 
 
4.4 Syndecan-1 and syndecan-2 downregulation in HeLa cells 
 
We have demonstrated the significance of syndecan-1 and syndecan-2 on HSV-1 
infection with selective gene silencing of syndecan-1 and syndecan-2 in HeLa cells using 
siRNA expression constructs [79]. Cells were treated with either syndecan-1- or syndecan-2-
specific siRNA to downregulate syndecan-1 and syndecan-2 gene expression, respectively. 
Gene silencing of syndecan-1 (Fig. 8a) and syndecan-2 (Fig. 8b) was detected at the protein 
level by using Western blot analysis. Densitometric analysis showed that treatment with 
syndecan-1- and syndecan-2-specific siRNA resulted in a significant (about 50%) reduction in 
syndecan-1 and syndecan-2 protein expression, respectively. The effect of siRNA was 
specific since scrambled siRNA failed to bring down syndecan expression and likewise, 
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neither scrambled nor syndecan-specific siRNAs had any effects on β-actin expression. 
Additional experiments (data not shown) demonstrated that siRNA against syndecan-1 was 
specific to its subtype and did not interfere with the expression of syndecan-2 and vice versa 
syndecan-2 siRNA also demonstrated high specificity. 
 
 
 
 
Figure 8. Western blot analysis of syndecan-1 and syndecan-2 protein expression after siRNA 
downregulation. Protein expression of syndecan-1 and syndecan-2 measured in a sample of HeLa cells mock 
treated (no transfection) or treated with scrambled siRNA, syndecan-1 siRNA or syndecan-2 siRNA for 48 h. 
Representative Western blots showed knockdown of syndecan-1 (a) or syndecan-2 (b) after siRNA 
downregulation. Densitometric analysis revealed 50% reduction in the signal intensity of both syndecan-1 and 
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syndecan-2. β-actin protein expression was measured as a loading control. (means ± SD from three independent 
experiments). 
 
4.5 Downregulation of syndecan-1 and syndecan-2 inhibits HSV-1 entry 
 
After verifying syndecan-1 and syndecan-2 downregulation by siRNA transfection, the 
effect of reduced syndecan-1 and syndecan-2 protein levels on HSV-1 entry into HeLa cells 
was examined. A previously described HSV-1 entry assay [71, 157] was used to compare 
viral entry into cells treated with syndecan-1 or syndecan-2 siRNA with those treated with 
scrambled siRNA or mock treated. HeLa cells were infected with a recombinant β-
galactosidase expressing HSV-1 (KOS) gL86 reporter virus. The entry of HSV-1 was 
measured after 6 h of viral infection. As indicated in Fig. 9a, a statistically significant, 26.6 ± 
4.6% inhibition of HSV-1 entry was observed in cells transfected with syndecan-1 siRNA 
(p<0.05). Transfected cells with syndecan-2 siRNA resulted in an even more significant, 64.9 
± 5.5% inhibition of HSV-1 entry (p<0.0001) (Fig. 9b).  
 
 
 
 
Figure 9. Downregulation of syndecan-1 and syndecan-2 inhibits HSV-1 entry into HeLa cells. HSV-1 
entry was analysed in HeLa cells mock treated (no transfection) or transfected with scrambled siRNA, syndecan-
1 siRNA or syndecan-2 siRNA. After siRNA transfection, cells were inoculated with a serial dilution of β-
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galactosidase expressing recombinant HSV-1 (KOS) gL86 virus for 6 h. The soluble substrate ONPG was added 
and enzymic activity was measured. Downregulation of both syndecan-1 (Fig. 8a) and syndecan-2 (Fig. 8b) 
inhibits HSV-1 (KOS) gL86 entry into HeLa cells although syndecan-2 siRNA has more significant effect. 
Percentage of inhibition of HSV-1(KOS) gL86 entry by syndecan-1 siRNA or syndecan-2 siRNA treatment was 
calculated relative to mock-treated (no transfection) cells. Scrambled siRNA-transfected cells were used as 
negative control. (means ± SD from six independent experiments; *p<0.05, **p<0.0001). 
 
4.6 Anti-syndecan-1 and anti-syndecan-2 polyclonal antibodies (pAbs) block HSV-1 entry 
 
To confirm the role of syndecan-1 and syndecan-2 in HSV-1 entry and to determine 
whether reduced HSV-1 entry after syndecan-1 and syndecan-2 knockdown is specific to 
syndecan ectodomains, a previously described antibody blocking assay [156] and pAbs 
blocking syndecan-1 and syndecan-2 ectodomains were utilized. As shown in Figure. 10, 
pAbs specific for the extracellular region of syndecan-1 or syndecan-2 were able to block 
HSV-1 entry into HeLa cells in a dose-dependent manner. At the maximum pAb 
concentration (4 µg per well) the observed inhibitions were 35.7 ± 4.2 and 57.84 ± 6.5 %, 
respectively, compared with HeLa cells that were treated with a control, anti-myc mAb. 
Although both syndecan-1 and syndecan-2 pAbs reduced HSV-1 entry, syndecan-2 pAbs 
blockade had a statistically significant reducing effect (p<0.05) that was more substantial than 
that caused by syndecan-1 pAbs treatment. The effect of the pAbs was not additive, since a 
cocktail containing both antibodies did not result in a stronger inhibition beyond what was 
seen with syndecan-2 pAbs (data not shown). 
 
 39 
 
 
 
Figure 10. Syndecan-1- or syndecan-2-specific antibody treatment blocked HSV-1(KOS) gL86 entry into 
HeLa cells. Cells were incubated with a serial dilution of syndecan-1-specific pAbs, syndecan-2-specific pAbs, 
or control anti-myc mAb for 30 min. Cells were then inoculated with a constant dose of β-galactosidase-
expressing recombinant HSV-1(KOS) gL86 (m.o.i. of 10) for 2 h. The soluble substrate ONPG was added and 
enzymic activity was measured. Per cent inhibition of HSV-1(KOS) gL86 entry by syndecan-1 pAbs or 
syndecan-2 pAbs treatment was calculated relative to anti-myc mAb-treated cells. (means ± SD from four 
independent experiments; *p<0.05) 
 
4.7 Downregulation of syndecan-1 and syndecan-2 inhibits plaque formation, reduces the size 
of HSV-1 plaques and enhances cell survival 
 
The ability of HSV-1 to form plaques reflects its ability to enter cells, replicate and 
spread to infect neighbouring uninfected cells. Since the downregulation of syndecan-1 and 
syndecan-2 reduced HSV-1 entry, we wanted to determine whether a similar decrease in 
HSV-1 plaque formation and spread in HeLa cells is also observed after syndecan-1 and 
syndecan-2 downregulation by siRNA transfection. To this end, a standard plaque assay was 
performed [157]. As shown in Figure 11a, there was a clear and significant reduction in the 
number of plaques formed in HeLa cells transfected with syndecan-1- and syndecan-2-
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specific siRNAs compared with mock treated or scrambled siRNA-transfected cells. 
Transfection with syndecan-1-specific siRNA reduced plaque number by 63.22 ± 2.65% 
(p<0.0001), while transfection with syndecan-2-specific siRNA reduced plaque number by 
98.73 ± 5.78% (p<0.0001). Images taken of formed plaques show that the downregulation of 
syndecan-1 and syndecan-2 resulted in the formation of smaller plaques compared to those of 
mock-treated or scrambled siRNA-treated cells (Fig. 11b).  
To prove that the reduction in entry and plaque formation is an effect of syndecan 
downregulation, and not a result of increased cell death, dead cells in each condition were 
counted 120 h after HSV-1 infection and the numbers were normalized to those observed with 
mock-treated cells. As shown in Figure 10c, downregulation of syndecan-1 reduced the 
percentage of dead cells after HSV-1 infection (by 33.06 ± 5.89 %), and downregulation of 
syndecan-2 resulted in a statistically significant decline in the percentage of dead cells (by 
80.45 ± 5.68 %, p<0.05).  
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Figure 11. Downregulation of syndecan-1 and syndecan-2 affects HSV-1 plaque formation, size and 
enhances cell survival in HeLa cells. Cells were either mock treated (no siRNA transfection), or treated with 
scrambled siRNA, syndecan-1 siRNA or syndecan-2 siRNA. Cells 48 h post-transfection were infected with 
HSV-1(KOS) (m.o.i. of 0.01). (a) Post-infection infectivity at 72 h was assessed by counting p.f.u. Relative 
number of plaques was computed relative to mock-treated (no siRNA transfection) samples. Significant 
decreases in number of plaques were seen in both syndecan-1 siRNA- and syndecan-2 siRNA-transfected HeLa 
cells. Plaques that consisted of 15 or more nuclei were counted. (means±SD from four independent experiments 
conducted in triplicate; **p<0.0001) (b) Morphological appearance of Giemsa-stained HSV-1 (KOS) plaques 72 
h post-infection. In syndecan-1 siRNA- and syndecan-2 siRNA-treated HeLa cells smaller plaques were 
observed compared to the plaques in mock-treated or scrambled siRNA-treated cells. Magnification, x40. (c) 
Cytotoxicity was measured 120 h after HSV-1 (KOS) infection. Relative number of dead cells was calculated 
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relative to mock-treated (no siRNA) samples. Significant decreases of cytotoxicity were observed in both 
syndecan-1 siRNA- and syndecan-2 siRNA treated cells; however, only the effect of syndecan-2 siRNA 
treatment was statistically significant. (means ± SD from four independent experiments conducted in triplicate; 
*p<0.05). 
 
4.8 PRINS expression is regulated differentially in NHKs and HaCaT cells upon stess 
induction 
 
In another set of experiments we aimed to investigate the role of the PRINS non-
coding RNA in LPS-induced stress response of keratinocytes. These experiments were carried 
out using both NHKs and an immortalized keratinocyte cell line, the HaCaT. To this end we 
first compared the PRINS expression of these two cell types upon various stress inductions. 
As shown previously, HaCaT cells and NHKs exhibited different PRINS expression patterns 
subsequent to various forms of stress induction: while translation inhibition, UV-B irradiation 
and co-incubation with microbial compounds all induced marked PRINS expression in 
HaCaT cells, in NHKs the same stressors either induced PRINS with a differential pattern 
(translation inhibition with cycloheximide and UV-B irradiation) or did not induce PRINS 
expression (microbial compounds) [38]. These data indicate a differential role for PRINS in 
the cellular stress response in NHKs and in the immortalized HaCaT cells. 
These gene expression experiments were performed by my coauthor, Dr. Lilla Bari 
and will be presented in detail in her PhD thesis. 
 
4.9 Silencing of PRINS expression does not affect the LPS-induced NF-κB response either in 
HaCaT cells or in NHKs 
 
A number of reports have indicated that immortalized HaCaT cells and NHKs exhibit 
differences in stress response, partially due to the aberrant NF-κB activity seen in HaCaT cells 
[161]. We set out to investigate whether the differences in PRINS-NF-κB interactions might 
be responsible for the differential PRINS expression in these two cell types. Since NF-κB 
activation is considered an end-point of signal transduction processes of cellular stress 
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response, we applied an experimental set-up in which the effect of PRINS silencing on LPS-
induced NF-κB activation could be studied both in HaCaT cells and in NHKs. 
Silencing of PRINS gene expression in NF-κB-HaCaT cells and in NHKs transfected 
with the AK696 PRINS specific silencing construct assessed by real-time RT-PCR, indicated 
effective silencing, to the extent of 70.66 ± 17.47% and 72.05 ± 22.78%, respectively as 
compared with cells transfected with the control SC1313 construct shown in Figure 12.  
 
 
 
 
 
Figure 12. Downregulation of PRINS ncRNA using the AK696 PRINS-specific silencing construct in NF-
κB-HaCaT cells and NHKs. (a) NF-κB-HaCaT cells were transfected with the PRINS silencing pSilencer 2.1-
U6 construct (AK696) and a construct harboring a scrambled sequence of PRINS gene (SC1313) and (b) NHKs 
were simultaneously co-transfected with the NF-κB-luc plasmid and either with the PRINS silencing pSilencer 
2.1-U6 construct (AK696) or with control construct (SC1313). PRINS expression was determined by reverse 
transcriptase real time PCR analysis. Data are indicated as fold expression compared with the controls (SC1313). 
(means ± SD from three independent experiments). 
 
Our results indicated that gene-specific PRINS silencing did not affect the LPS-
induced NF κB activity either in HaCaT cells (Fig. 13a) or in NHKs (Fig. 13b). In HaCaT 
cells, we saw no change in NF-κB signal in transfected cells, while in NHKs a non-specific 
effect was seen in both the control and the specific silencing construct-transfected cells. LPS 
treatment induced a significant three- to four-fold NF-κB activation in HaCaT cells and in 
NHKs, but this induction was not affected by PRINS silencing in either cell types. This 
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suggests that PRINS is not an upstream effector of NF-κB signalling in keratinocytes, and that 
the observed differences in stress-induced PRINS expression in HaCaT cells and in NHKs are 
not related to the aberrant NF-κB activity of HaCaT cells. We therefore hypothesize that 
PRINS may signal independently of NF-κB, and another novel cellular processes may lie 
behind the differences in stress-induced PRINS expression between the two cell types. 
 
 
 
 
 
Figure 13. The effects of PRINS silencing on LPS-induced NF-κB activity in HaCaT cells and in NHKs. 
Luciferase assays were performed to assess NF-κB activity in response to LPS stimulation in NF-κB-HaCaT 
cells (a) and in NHKs (b). Silencing of PRINS had no effect on the LPS-induced NF-κB activity either in HaCaT 
cells or in NHKs. 
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5. DISCUSSION 
 
Epithelial cells compose the covering of most internal and external surfaces of the 
human body including the outer layer of the skin (epidermis), as well as the surface of most 
body cavities including the respiratory, the gastrointestinal, the reproductive and the urinary 
tract. The surface of exocrine and endocrine glands is also composed by epithelial cells. 
Epithelial cells constitute the first defense line against invading pathogens and have a 
proactive role in immune responses and the development of localized inflammatory 
conditions. To protect the human body and respond to stress conditions caused by microbial 
infection, epithelial tissue apply three main strategies. Firstly, epithelial cells form an 
impermeable physical barrier that prevents pathogen entry; secondly epithelial cells are able 
to produce defense molecules including antimicrobial peptides and proteinase inhibitors; 
finally these cells can produce and release signaling molecules including lipid mediators, 
grow factors, and variety of cytokines/chemokines [162, 163]. These signaling molecules 
activate cells of the innate and adaptive immune system [164]. 
Investigations on the molecular mechanisms of epithelial cell stress responses to 
pathogen invasion has great importance for our better understanding of the pathogenesis of 
diseases and indentifying novel therapeutic targets. Our aim was to investigate two aspects of 
stress responses of epithelial cells triggered by viral or bacterial induction.  
In our first model system, HSV-1 was chosen as a viral induction agent since it is a 
clinically important pathogen and leads to numerous diseases from oral lesions to more severe 
conditions. Currently, no cure exists against HSV-1 therefore expansion of our understanding 
of HSV-1–host cell interactions has a great significance on the prevention and treatment of 
HSV-1 viral infection. The initial contact of HSV-1 with its principal target epithelial cells is 
the binding of the virus to HS chains which are expressed on the cell surface as HSPGs [51, 
165]. HS can serve as a receptor for a wide range of microbial pathogens, including viruses 
and bacteria [166-168]. Although the role of HS is well studied as an attachment receptor for 
HSV-1, the role of HSPG core proteins in HSV-1 infection is poorly understood. Since 
predominant HSPGs on human epithelial cell surfaces are syndecan-1 and syndecan-2, [84] 
we aimed to explore the role of their core proteins in HSV-1 infection. The first part of our 
studies directly implicates two members of the syndecan family of HSPGs, syndecan-1 and 
syndecan-2, as important mediators of HSV-1 infection.  
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Previous studies have shown that the infection with various microbial pathogens can 
modulate the expression levels of different syndecan family members. For example, 
alterations in syndecan-1 expression level are observed during the infection with 
Pneumocystis jiroveci and Neisseria gonorrhoeae [34, 35]. Epstein–Barr virus infection 
results in the downregulation of syndecan-1 [33]. Our study is the first report of HSV-1 
infection modulating the expression levels of syndecan-1 and syndecan-2 in infected cells. We 
demonstrated that HSV-1-induced syndecan-1 and syndecan-2 expression enhancements 
occur both at the cell surface level and also at the protein synthesis level. Interestingly, our 
findings suggest that an increase in syndecan-1 and syndecan-2 expression levels, although 
important for many reasons, may also be used as a marker for active HSV-1 infection. Further 
experiments are needed to understand mechanisms by which HSV-1 upregulates syndecan-1 
and syndecan-2 expression and to determine whether this upregulation is a result of a specific 
signaling pathway activation by the virus. 
Additionally, we demonstrate that both syndecan-1 and syndecan-2 contribute 
significantly to viral entry and spread. Knocking down of either syndecan-1 or syndecan-2 
shows detectable effects on HSV-1 entry and plaque formation. Our results also suggest that 
syndecan-2 may have a distinctly larger role in HSV-1 infection than syndecan-1. In addition, 
we provide evidence to directly implicate the HSPG core protein in viral entry. Many known 
protein receptors for HSV-1 entry can be blocked by antibodies, which in turn, blocks viral 
entry [157, 169]. Similar to those receptors, we also found that pAbs against synedecan-1 and 
syndecan-2 block entry. While it is quite possible that antibodies may act by producing steric 
hinderance to virus binding via HS, it is also possible that the core protein may directly 
interact with HSV-1 glycoproteins and that interaction is blocked by the antibodies. For 
unclear reasons, the syndecan pAbs when combined together did not produce an additive 
effect. Future studies will determine whether the syndecan pAbs (especially syndecan-2 
pAbs) may cross-react to block certain conserved syndecan epitopes shared for entry. In this 
case, one group of pAbs (e.g. syndecan-2 pAbs) may be able to block all the epitopes 
(whether on syndecan-1 or syndecan-2) and therefore, pAbs to another protein may not be 
able to show any additional effects. Alternatively, a second possibility is that the pAbs may be 
able to block low affinity interactions (or create steric hindrance) that do not involve 
conformational changes. However, high affinity interactions (accompanied by conformation 
 47 
changes) may not be blocked by antibodies and therefore, the net effect by combining the 
antibodies may not be significantly higher than the individual effects. This may be a reason 
why a near complete blocking of HSV-1 infection by antibodies has been extremely rare even 
when all gD receptors were blocked [157, 169]. Our results, nevertheless, highlight that 
syndecan-1 and syndecan-2 both play a critical role during HSV-1 entry and that the two 
HSPGs show detectable differences in their abilities to facilitate infection. A related 
interesting finding was that the effect of syndecan-2 knockdown was even more severe at the 
plaque formation level. Unlike entry, the downregulation of syndecan-2 expression almost 
completely inhibited plaque formation in HeLa cells. A reduction in plaque number was 
expected since we found that downregulation of syndecan-1 and syndecan-2 reduces HSV-1 
entry. However, the observed dramatic reduction in plaque formation raises the possibility 
that reduced virus entry may not be the only reason for reduced plaque formation and that an 
additional role for syndecan-2 in HSV-1 replication or spread could not be ruled out. Since 
syndecans participate in endocytosis, they may affect virus transport as well [170]. One 
possible way to explain the fact that syndecan-2 has a more significant role in HSV-1 entry is 
related to the differences in GAG distribution on the ectodomains of the HSPGs. While the 
syndecan-1 ectodomain carries HS and chondroitin sulfate (CS) chains, syndecan-2 carries 
solely HS chains on its ectodomain [83, 88, 171]. It is possible that the presence of HS alone 
may help reduce any non-specific virus binding generated by similarly charged but less 
effective CS. A second way to explain the observable differences relies on HSPG cytoplasmic 
domain that has been shown to interact with a variety of signalling and structural proteins, 
suggesting its involvement in various regulatory phenomena. The cytoplasmic domain 
consists of two conserved regions, a membrane proximal common region (C1) and C-terminal 
common region (C2). C2 mediates binding to cytoskeletal proteins and to PDZ-containing 
proteins [81, 172, 173]. The C1 and C2 conserved regions are separated by a variable region 
(V) that is unique for each of the four syndecan family members [81, 172]. The difference in 
the variable region in syndecan-1 and syndecan-2 might explain how these two syndecans 
might have different regulatory roles during HSV-1 infection through activating different 
cellular pathways. Further understanding of the role of the syndecans in HSV-1 infection 
could identify novel antiviral targets and lead to the development of improved antiviral 
strategies. 
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In our second model system, we aimed to elucidate the putative role of a novel non-
coding RNA, PRINS in NF-κB signaling pathway activation in human keratinocytes 
following bacterial LPS induction as an epidermal stress factor. 
Previously, we identified a novel non-coding RNA (ncRNA), PRINS that was 
overexpressed in the non-involved epidermis of psoriatic patients as compared with epidermis 
of healthy individuals [37]. PRINS, localized on the short arm of human chromosome 10, 
consists of two exons, and its full length transcript, expressed by the immortalized 
keratinocytes cell line HaCaT, is 3.6 kb long [37]. PRINS harbours two Alu repetitive 
sequences, and also contains a heat-shock element that displays approximately 70% similarity 
to G8, a small ncRNA in Tetrahymena thermophila [37]. Various stress signals, such as 
serum starvation, contact inhibition, UV-B irradiation, viral (HSV-1) infection and 
translational inhibition by cycloheximide, induced the expression of PRINS in HaCaT cells 
[37]. The effects of stressors were apparent as early as 0.5–3 h after the application of stress, 
indicating that PRINS may play a role in the early phase of the cellular stress response [37]. 
Gene-specific silencing of PRINS led to a decreased viability of serum-starved HaCaT 
keratinocytes as opposed to the control cells, where the silencing of PRINS under the normal 
culturing conditions did not have an impact on cellular viability [37]. These data led us to 
hypothesize that PRINS is essential for the survival of keratinocytes under stress conditions. 
In a next set of experiments we compared PRINS expression patterns in HaCaT cells 
and NHKs. We analyzed  PRINS expression after treatment with cycloheximide (a chemical 
inhibitor of mRNA translation), UV-B irradiation and incubation with several microbial 
compounds inluding Candida albicans, LPS, Staphylococcus aureus peptidoglycan or 
Mycobacterium tuberculosis extract in both NHKs and HaCaT cells [38]. We found that 
PRINS expression responded differentially to various stress signals and microbial agents in 
HaCaT cells and in NHKs.  
Epidermotropic viruses exert a series of structural and biochemical changes in invaded 
host cells, one of which is translational inhibition. Incubation of HaCaT cells and NHKs with 
cycloheximide, a chemical inhibitor of mRNA translation, resulted in elevations of PRINS 
expression of similar magnitude, but with different time courses in the two cell types [38]. 
Exposition of HaCaT cells and NHKs to UV-B irradiation resulted in a gentle, prolonged 
PRINS expression response in HaCaT cells and a late, significant PRINS expression response 
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in NHKs, respectively [38]. It is well documented that distinct differences exist between the 
responses of NHKs and HaCaT cells to UV-B irradiation and HaCaT cells are known to be 
more sensitive to UV-B-induced apoptosis [174]. However, the most striking differences we 
saw between the two cell types in PRINS expression were after  incubation with microbial 
compounds: while PRINS expression in HaCaT cells was highly elevated in response to all of 
applied microbial agents, a significant elevation of PRINS expression in NHKs was observed 
only after incubation with LPS, but none of the other microbial agents [38].  
Under normal conditions, the epidermis is subjected to a wide range of pathogenic and 
non-pathogenic microbes, which can activate the innate immune system through a variety of 
pattern recognition receptors, such as the family of TLRs. It is well established that signaling 
events induced by LPS stimulation are mediated through TLR 4 [175], while yeast and Gram-
positive bacterial and mycobacterial components bind to TLR 2 [176]. The effect of LPS is 
mediated through TLR4 in keratinocytes.  Keratinocytes also express TLR2, a receptor to 
yeast and Gram-positive bacterial and mycobacterial components [177]. Olariu et al. 
previously demonstrated that HaCaT cells and NHKs expressed similar levels of TLR2 and 
TLR4 mRNAs, and that HaCaT cells stimulated with various microbial agents responded with 
the induction of various chemokine mRNAs similarly to NHKs [178]. Taken together, these 
data suggest that, although HaCaT cells exhibit differences in some applications i.e. 
regulation of tissue differentiation [179], they are suitable tools for studying certain aspects of 
keratinocyte functions. We supposed that detected differences in microbial compound-
induced PRINS expression may not be related to TLR-mediated signal transduction events in 
these two cell types.  
Since NF-κB is considered to be a down-stream effector in signal transduction, we 
investigated whether PRINS is involved in the regulation of signaling events leading to NF-
κB activation. To reveal whether NF-κB transduction pathway is affected by the PRINS non-
coding RNA, we silenced the PRINS gene expression with siRNA in NHKs and HaCaT 
keratinocytes and monitored NF-κB signal transduction after LPS treatment. Our results 
demonstrated that PRINS gene silencing had no effect on NF-κB activation either in NHKs or 
in HaCaT cells, suggesting that PRINS is not an upstream effector of NF-κB signalling in 
keratinocytes. To identify which signal transduction events are affected by the PRINS 
ncRNA, further studies are needed. The results of our previous work [180] suggested that 
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PRINS may primarily contribute to cellular events regulating keratinocyte apoptosis, since we 
found that PRINS regulated the expression of G1P3, an anti-apoptotic gene that is under the 
control of the JAK/STAT/ISRE signal transduction pathway [181]. Overall, our data indicate 
that PRINS, a novel ncRNA related to the cellular stress response [37], signals independently 
of the NF-κB-mediated signal transduction pathway(s). Moreover, our results suggest that 
there may be differences in intracellular signaling pathways between NHKs and HaCaT cells 
and this is also reflected in the differences in PRINS expression seen in these two cell types. 
The identification of genes with altered expression patterns either in involved or in 
non-involved psoriatic skin widely contributes to the better understanding of the pathogenesis 
of psoriasis. Previous studies have been revealed large scale gene expression changes in 
involved psoriatic skin compared to normal skin [134, 136, 137]; involved psoriatic skin 
compared to non-involved psoriatic skin [136, 137, 140]; and non-involved psoriatic skin 
compared to normal skin [139]. While numerous psoriasis-associated genes have been 
identified [117, 134, 137, 139, 140], the role of these genes in the pathogenesis of psoriasis 
remains poorly understood. Previously, we identified a novel non-coding RNA, PRINS that is 
expressed at higher level in the non-involved epidermis of psoriatic patients than in either the 
psoriatic involved epidermis or epidermis of healthy individuals [37]. Our results suggest that 
the overexpression of PRINS in the non-involved psoriatic epidermis may play role in 
psoriasis susceptibility [37] and are in accordance with previous studies that in response to 
external stress stimuli, the keratinocytes of the non-involved psoriatic and of the healthy 
epidermis answer differentially [182, 183]. We additionally showed that the expression of the 
anti-apoptotic G1P3 gene is under the contol of PRINS [148] and PRINS might interact 
physically with the molecular chaperone protein nucleophosmin in keratinocytes [148]. We 
suppose that PRINS is part of a ribonucleocomplex and its altered expression in psoriatic 
uninvolved epidermis contributes to the well-established aberrant stress response of psoriatic 
keratinocytes and as a consequence to psoriasis susceptibility. 
Human epithelial surfaces have a great importance in defense mechanisms against 
invading organisms. Infection of epithelial cells by microbial pathogens activates numerous 
host protective molecular mechanisms which are coordinated by a complex program of gene 
expression. A better understanding of HSV-1/host interaction mechanisms and the role of a 
novel ncRNA in the pathogenesis of psoriasis will be useful for screening and evaluating 
 51 
possible therapeutic strategies and may provide some novel base for development of new 
strategies for the treatment of infectious and inflammatory diseases.  
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6. SUMMARY 
 
In our work, we investigated two aspects of epithelial cell stress responses following 
viral and bacterial infection.  In the first part of our work, we examined the role of two 
heparan sulfate proteoglycans on HSV-1 infection and in the second part of our work we 
examined the connection between the NF-κB and PRINS-mediated signal transduction 
pathway in NHKs and HaCaT cells. 
Herpes simplex virus type 1 (HSV-1) is an important human pathogen and a leading 
cause of infectious blindness in the developing world. HSV-1 exploits heparan sulfate 
proteoglycans (HSPG) for attachment to cells. While the significance of heparan sulphate 
(HS) moieties in HSV-1 infection is well established, the role of specific proteoglycan core 
proteins in the infection process remains poorly understood. The objective of this study was to 
assess the roles of syndecan-1 and syndecan-2 core proteins in HSV-1 infection, both of 
which are expressed by many HSV-1 target cell types. HSV-1 infection increases syndecan-1 
and syndecan-2 protein synthesis and results increase in cell surface expression of HS. 
Furthermore, our results demonstrate that syndecan-1 and syndecan-2 gene silencing by RNA 
interference reduces HSV-1 entry, plaque formation and facilitates cell survival. Our 
observations suggest that changes in syndecan-1 and syndecan-2 expression levels may be 
related to active viral infection. Taken together, our findings provide new insights into HSPG 
functions during HSV-1 entry and spread. 
Psoriasis is a chronic inflammatory skin disease that affects approximately 2–4% of 
the population. We recently described a novel non-coding RNA, psoriasis susceptibility 
related RNA gene induced by stress (PRINS), that was overexpressed in non-lesional psoriatic 
epidermis, and its expression was induced by various stress factors such as serum starvation, 
contact inhibition, ultraviolet (UV)-B irradiation, viral infection and translational inhibition in 
HaCaT cells. We compared the stress and microbial agent-induced PRINS expression in 
normal human keratinocytes (NHKs) and HaCaT cells and we observed different PRINS 
expression pattern responded to various stress signals and microbial agents in these two cell 
lines. To explore whether the known NF-κB abnormalities in HaCaT cells could be related to 
this differential PRINS expression, we silenced the PRINS gene expression with small 
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interfering RNA (siRNA) in both HaCaT cells and in NHKs and monitored NF-κB signal 
transduction after lipopolysaccharide (LPS) treatment. Silencing of PRINS had no effect on 
LPS-induced NF-κB activity either in HaCaT cells or in NHKs. Our results indicate that 
PRINS probably affects keratinocytes functions independently of NF-κB signalling. 
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7. ÖSSZEFOGLALÁS 
 
Munkánk célja a virális és a bakteriális fertızést követı sejtszintő stressz válaszok 
tanulmányozása volt epithél sejtekben. Munkánk elsı részében két, a herpes simplex virus-1 
(HSV-1) fertızésre fogékony sejtek felszínén általánosan kifejezett sejtfelszíni heparán-
szulfát proteoglikán (HSPG), a syndecan-1 és syndecan-2 szerepét tanulmányoztuk a HSV-1 
fertızésben human epithél sejtekben (HeLa), míg munkánk második részét az NF-κB és 
PRINS-közvetített jelátviteli útvonal közti kapcsolat vizsgálata képezte primer 
keratinocitákban és HaCaT -sejtekben. 
A herpes simplex-1 világszerte elterjedt patogén vírus. A HSV-1 által leggyakrabban 
okozott betegségek a bır felhólyagosodásával járó ajak-herpesz; a vakságot is okozható 
szaruhártyaherpesz, de ritka esetekben a lappangó HSV-1 vírus aktivációja akár encephalitist 
(herpes-encephalitis) is elıidézhet. A herpeszfertızés a sérült bır vagy nyálkahártya epithél 
sejtjeiben megy végbe. Az elsıdleges fertızést követıen a HSV-1az érzıideg-végzıdésekbe 
jut, majd az idegnyúlványokon keresztül a gerincvelı hátsó gyöki ganglionjaiban telepszik 
meg, és lappang élethossziglan. A szervezetben lappangó herpeszvírusok reaktiválódhatnak 
különbözı tényezık hatására, úgymint immunszupresszió, láz, hormonális változások, 
menstruáció, stresszhatások és UV-fény. 
A HSV-1 vírus a gazdasejtbe való bejutása egy többlépcsıs folyamat, ami a virális 
burok glikoprotein gB és gC heparán szulfátokhoz (HS) való kapcsolódásával kezdıdik. A HS 
a glükózaminoglikánok (GAG) családjába tartozó, heterogén szerkezető, lineáris 
poliszacharid, ami általánosan megtalálható az emlıs szöveti sejtek felszínén és az 
extracelluláris mátrixban. A HS- láncok fehérjékhez való kovalens kötıdésével 
proteoglikánok jönnek létre (HSPGs), amelyek sejtfelszíni receptorként/koreceptorként 
szolgálnak számos ligand számára. Míg a HS-láncoknak bizonyítottan fontos szerepe van a 
HSV-1 fertızésben, addig a HSPG-ok magfehérjéinek vírusfertızésben betöltött szerepérıl 
keveset tudunk. A syndecan család tagjai (syndecan-1, syndecan-2, syndecan-3 és syndecan-
4) általánosan megtalálható HSPG-ok az emlıs sejtek felszínén, továbbá a syndecan-1 és 
syndecan-2 fehérjék jelentıs mértékben kifejezıdnek a HSV-1 fertızés célsejtjeiként szolgáló 
epithél sejtek felszínén. Kutatásunk célja az volt, hogy betekintést nyerjünk a syndecan-1 és 
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syndecan-2 magfehérjék HSV-1 fertızésben betöltött szerepébe. Fehérje expressziós 
vizsgálatok segítségével megállapítottuk, hogy HSV-1 fertızést követıen a syndecan-1 és a 
syndecan-2 fehérjék szintézise megnövekedett mind sejtfelszíni, mind összfehérje szinten, 
továbbá RNS-interferencia módszerrel kimutattuk, hogy a syndecan-1 és syndecan-2 fehérjék 
mennyiségének csökkentése negatívan hat a HSV-1 vírusok gazdasejtbe történı bejutására, 
illetve a vírusfertızés terjedésére, és elısegíti a fertızött sejtek túlélését HeLa -sejtekben. 
Vizsgálataink arra engednek következtetni, hogy a syndecan-1 és syndecan-2 fehérjék 
mennyiségének változása kapcsolatban áll az aktív vírusfertızéssel. Összegezve, 
eredményeink új betekintést nyújtanak a HSPG-ok szerepérıl a HSV-1 gazdasejtbe való 
bejutásának és a vírus sejtrıl sejtre való terjedésének folyamatába.  
Munkánk második részében a kutatócsoportunk által korábban leírt nem kódoló RNS-
molekula (PRINS, Psoriasis Susceptibility Related RNA gene Induced by Stress) szerepét 
vizsgáltuk bakteriális lipopolysacharid kezelést követıen, mind immortalizált keratinocita 
sejtekben (HaCaT), mind elsıdleges keratinocyta tenyészetekben.  
A pikkelysömör (psoriasis) a populáció 2-4 %-án észlelhetı, és világszerte 120-180 
millió embert érintı krónikus gyulladásos tünetekkel járó multifaktoriális bırbetegség. A 
pikkelysömör pathomechanizmusa még nem ismert pontosan, de a tünetek megjelenésében 
örökletes genetikai faktorok, környezeti tényezık (a bır mechanikai, kémiai sérülése, 
ultraibolya-sugárzás, különféle fertızések vagy a gyógyszerhasználat) továbbá az 
immunfolyamatokban bekövetkezı abnormalitások is szerepet játszanak. A psoriasis fokozott 
keratinocita proliferációval, a gyulladást elısegítı sejtek epidermális infiltrációjával jár, ami a 
bır felszínén plakkok megjelenéséhez vezet. Noha a számos nagy skálájú génexpressziós 
vizsgálatoknak köszönhetıen tudjuk, hogy a pikkelysömörös epidermiszben több száz gén és 
fehérje kifejezıdése megváltozik, e gének és fehérjék pontos szerepérıl a pikkelysömörre 
való hajlam kialakításában keveset tudunk. A pikkelysömörre hajlamosító örökletes faktorok 
azonosítása lehetıséget nyújt új diagnosztikus eszközök, valamint preventív terápiás 
megoldások kidolgozására. 
Korábban valós idejő RT-PCR-kísérletek segítségével megállapítottuk, hogy a PRINS-
gén eltérı kifejezıdési mintázatot mutat a két általunk vizsgált sejtvonalban, egy 
fehérjeszintézis gátló molekula (cycloheximid), lipopolysaccharid (LPS) kezelést, illetve 
különbözı mikrobiális anyagokkal való kezelést követıen. A PRINS gén kifejezıdésének 
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növekedését észleltük a cycloheximid, illetve LPS-kezelést követıen HaCaT-sejtekben, 
ugyanez a primer keratinocitákban nem volt megfigyelhetı. Ugyancsak különbözı PRINS 
gén kifejezıdési mintázatot tapasztaltunk a két általunk vizsgált sejtvonalban mikrobiális 
anyagokkal való kezelést követıen: míg a PRINS nem-kódoló RNS kifejezıdésének markáns 
növekedését figyeltük meg HaCaT-sejtekben, addig a mikrobiális anyagokkal való kezelés 
nem váltott ki változást a PRINS kifejezıdésében primer keratinocitákban. 
Ismert, hogy a mikróbák epitél sejtek általi felismerését a nuclear factor-κB (NF- κB) 
jelátviteli út aktiválása követi. Annak eldöntésére tehát, hogy a két vizsgált sejtvonalban 
megfigyelt különbség hátterében a megváltozott NF-κB jelátvitel út áll-e, a PRINS nem- 
kódoló RNS kifejezıdését csökkentettük kis interferáló RNS-ek (siRNS) segítségével HaCaT-
sejtekben és a primer keratinocitákban, melyeket elızetesen NF-κB válaszelemet, illetve 
luciferáz riporter gént tartalmazó konstrukttal transzfektáltunk.  Ezután a transzfektált 
sejtekben nyomon követtük az LPS-kezelés által kiváltott NF-κB aktivációt. Luciferáz riporter 
esszék segítségével megállapítottuk, hogy a PRINS gén csendesítése nem volt hatással az LPS 
kiváltotta NF-κB aktivitásra sem HaCaT-sejtekben, sem az elsıdleges keratinocitákban. 
Eredményeink arra engednek következtetni, hogy a PRINS nem-kódoló RNS az NF-κB-tıl 
független jelátvivı, vagy a jelátviteli kaszkádban az NF-κB után helyezkedik el. Az LPS-
kezelés hatására bekövetkezı eltérı PRINS gén aktiváció hátterében más, jelenleg még 
ismeretlen setjszintő folyamatok állhatnak.  
 57 
8. REFERENCES 
 
1. Calabrese V, Cornelius C, Dinkova-Kostova AT & Calabrese EJ (2009) Vitagenes, 
cellular stress response, and acetylcarnitine: relevance to hormesis. Biofactors 35, 146-160. 
2. Kultz D (2003) Evolution of the cellular stress proteome: from monophyletic origin to 
ubiquitous function. J Exp Biol 206, 3119-3124. 
3. Bartek J & Lukas J (2001) Pathways governing G1/S transition and their response to 
DNA damage. FEBS Lett 490, 117-122. 
4. Bulavin DV, Amundson SA & Fornace AJ (2002) p38 and Chk1 kinases: different 
conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev 12, 92-97. 
5. Brostrom CO & Brostrom MA (1998) Regulation of translational initiation during 
cellular responses to stress. Prog Nucleic Acid Res Mol Biol 58, 79-125. 
6. Feder ME & Hofmann GE (1999) Heat-shock proteins, molecular chaperones, and the 
stress response: evolutionary and ecological physiology. Annu Rev Physiol 61, 243-282. 
7. Kato K, Ito H, Iwamoto I, Lida K & Inaguma Y (2001) Protein kinase inhibitors can 
suppress stress-induced dissociation of Hsp27. Cell Stress Chaperones 6, 16-20. 
8. Harkin DP & Hall PA (2000) Measuring a cell's response to stress: the p53 pathway. 
Genome Biol 1, REVIEWS105. 
9. Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S & Wiesmuller L NF-
kappaB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP 
complexes. Nucleic Acids Res 40, 181-195. 
10. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E & Kroemer G (2006) Heat 
shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5, 
2592-2601. 
11. Ashida H, Mimuro H, Ogawa M, Kobayashi T, Sanada T, Kim M & Sasakawa C Cell 
death and infection: a double-edged sword for host and pathogen survival. J Cell Biol 195, 
931-942. 
12. Nipic D, Pirc A, Banic B, Suput D & Milisav I Preapoptotic cell stress response of 
primary hepatocytes. Hepatology 51, 2140-2151. 
13. Degterev A, Boyce M & Yuan J (2003) A decade of caspases. Oncogene 22, 8543-
8567. 
14. Samali A (2007) Apoptosis: a mapped path to cell death. J Cell Mol Med 11, 1212-
1213. 
15. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson 
CB & Tsujimoto Y (2004) Role of Bcl-2 family proteins in a non-apoptotic programmed cell 
death dependent on autophagy genes. Nat Cell Biol 6, 1221-1228. 
16. Eskelinen EL (2008) New insights into the mechanisms of macroautophagy in 
mammalian cells. Int Rev Cell Mol Biol 266, 207-247. 
17. Luo S & Rubinsztein DC Apoptosis blocks Beclin 1-dependent autophagosome 
synthesis: an effect rescued by Bcl-xL. Cell Death Differ 17, 268-277. 
18. Sengupta S, Peterson TR & Sabatini DM Regulation of the mTOR complex 1 pathway 
by nutrients, growth factors, and stress. Mol Cell 40, 310-322. 
19. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N & Vandenabeele P 
(2008) Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 8, 
207-220. 
 58 
20. Golstein P & Kroemer G (2007) Cell death by necrosis: towards a molecular 
definition. Trends Biochem Sci 32, 37-43. 
21. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ & Yuan J (2008) 
Identification of a molecular signaling network that regulates a cellular necrotic cell death 
pathway. Cell 135, 1311-1323. 
22. Proskuryakov SY, Konoplyannikov AG & Gabai VL (2003) Necrosis: a specific form 
of programmed cell death? Exp Cell Res 283, 1-16. 
23. Zhu C, Wang X, Xu F, Bahr BA, Shibata M, Uchiyama Y, Hagberg H & Blomgren K 
(2005) The influence of age on apoptotic and other mechanisms of cell death after cerebral 
hypoxia-ischemia. Cell Death Differ 12, 162-176. 
24. Meylan E & Tschopp J (2005) The RIP kinases: crucial integrators of cellular stress. 
Trends Biochem Sci 30, 151-159. 
25. Bergsbaken T, Fink SL & Cookson BT (2009) Pyroptosis: host cell death and 
inflammation. Nat Rev Microbiol 7, 99-109. 
26. Medzhitov R & Janeway C, Jr. (2000) Innate immunity. N Engl J Med 343, 338-344. 
27. Chen GY & Nunez G Sterile inflammation: sensing and reacting to damage. Nat Rev 
Immunol 10, 826-837. 
28. Davis BK, Wen H & Ting JP The inflammasome NLRs in immunity, inflammation, 
and associated diseases. Annu Rev Immunol 29, 707-735. 
29. Thompson AJ & Locarnini SA (2007) Toll-like receptors, RIG-I-like RNA helicases 
and the antiviral innate immune response. Immunol Cell Biol 85, 435-445. 
30. Akira S, Uematsu S & Takeuchi O (2006) Pathogen recognition and innate immunity. 
Cell 124, 783-801. 
31. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L & Gattegno L 
(2006) The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary 
macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix 
metalloproteinase-9. Glycobiology 16, 488-501. 
32. Kubo T, Wada T, Yamaguchi Y, Shimizu A & Handa H (2006) Knock-down of 25 
kDa subunit of cleavage factor Im in Hela cells alters alternative polyadenylation within 3'-
UTRs. Nucleic Acids Res 34, 6264-6271. 
33. Anastasiadou E, Vaeth S, Cuomo L, Boccellato F, Vincenti S, Cirone M, Presutti C, 
Junker S, Winberg G, Frati L, Wade PA, Faggioni A & Trivedi P (2009) Epstein-Barr virus 
infection leads to partial phenotypic reversion of terminally differentiated malignant B cells. 
Cancer Lett 284, 165-174. 
34. Freissler E, Meyer auf der Heyde A, David G, Meyer TF & Dehio C (2000) Syndecan-
1 and syndecan-4 can mediate the invasion of OpaHSPG-expressing Neisseria gonorrhoeae 
into epithelial cells. Cell Microbiol 2, 69-82. 
35. Wang SH, Zhang C, Liao CP, Lasbury ME, Durant PJ, Tschang D & Lee CH (2006) 
Syndecan-1 expression in the lung during Pneumocystis infection. J Eukaryot Microbiol 53 
Suppl 1, S122-123. 
36. Shukla D & Spear PG (2001) Herpesviruses and heparan sulfate: an intimate 
relationship in aid of viral entry. J Clin Invest 108, 503-510. 
37. Sonkoly E, Bata-Csorgo Z, Pivarcsi A, Polyanka H, Kenderessy-Szabo A, Molnar G, 
Szentpali K, Bari L, Megyeri K, Mandi Y, Dobozy A, Kemeny L & Szell M (2005) 
Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA 
gene, PRINS. J Biol Chem 280, 24159-24167. 
 59 
38. Bari L, Bacsa S, Sonkoly E, Bata-Csorgo Z, Kemeny L, Dobozy A & Szell M 
Comparison of stress-induced PRINS gene expression in normal human keratinocytes and 
HaCaT cells. Arch Dermatol Res 303, 745-752. 
39. Reske A, Pollara G, Krummenacher C, Chain BM & Katz DR (2007) Understanding 
HSV-1 entry glycoproteins. Rev Med Virol 17, 205-215. 
40. Mettenleiter TC (2004) Budding events in herpesvirus morphogenesis. Virus Res 106, 
167-180. 
41. Whitley RJ & Roizman B (2001) Herpes simplex virus infections. Lancet 357, 1513-
1518. 
42. Mettenleiter TC (2003) Pathogenesis of neurotropic herpesviruses: role of viral 
glycoproteins in neuroinvasion and transneuronal spread. Virus Res 92, 197-206. 
43. Eisenstein LE, Calio AJ & Cunha BA (2004) Herpes simplex (HSV-1) aseptic 
meningitis. Heart Lung 33, 196-197. 
44. Whitley RJ & Gnann JW (2002) Viral encephalitis: familiar infections and emerging 
pathogens. Lancet 359, 507-513. 
45. Streilein JW, Dana MR & Ksander BR (1997) Immunity causing blindness: five 
different paths to herpes stromal keratitis. Immunol Today 18, 443-449. 
46. Nahmias AJ, Lee FK & Beckman-Nahmias S (1990) Sero-epidemiological and -
sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 
69, 19-36. 
47. Heldwein EE & Krummenacher C (2008) Entry of herpesviruses into mammalian 
cells. Cell Mol Life Sci 65, 1653-1668. 
48. Pertel PE, Fridberg A, Parish ML & Spear PG (2001) Cell fusion induced by herpes 
simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily 
heparan sulfate. Virology 279, 313-324. 
49. Spear PG, Eisenberg RJ & Cohen GH (2000) Three classes of cell surface receptors 
for alphaherpesvirus entry. Virology 275, 1-8. 
50. Turner A, Bruun B, Minson T & Browne H (1998) Glycoproteins gB, gD, and gHgL 
of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a 
Cos cell transfection system. J Virol 72, 873-875. 
51. Herold BC, WuDunn D, Soltys N & Spear PG (1991) Glycoprotein C of herpes 
simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. 
J Virol 65, 1090-1098. 
52. Karasneh GA & Shukla D Herpes simplex virus infects most cell types in vitro: clues 
to its success. Virol J 8, 481. 
53. Herold BC, Visalli RJ, Susmarski N, Brandt CR & Spear PG (1994) Glycoprotein C-
independent binding of herpes simplex virus to cells requires cell surface heparan sulphate 
and glycoprotein B. J Gen Virol 75 ( Pt 6), 1211-1222. 
54. Laquerre S, Argnani R, Anderson DB, Zucchini S, Manservigi R & Glorioso JC 
(1998) Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B 
and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell 
spread. J Virol 72, 6119-6130. 
55. Clement C, Tiwari V, Scanlan PM, Valyi-Nagy T, Yue BY & Shukla D (2006) A 
novel role for phagocytosis-like uptake in herpes simplex virus entry. J Cell Biol 174, 1009-
1021. 
 60 
56. Campadelli-Fiume G, Amasio M, Avitabile E, Cerretani A, Forghieri C, Gianni T & 
Menotti L (2007) The multipartite system that mediates entry of herpes simplex virus into the 
cell. Rev Med Virol 17, 313-326. 
57. Akhtar J & Shukla D (2009) Viral entry mechanisms: cellular and viral mediators of 
herpes simplex virus entry. FEBS J 276, 7228-7236. 
58. Milne RS, Nicola AV, Whitbeck JC, Eisenberg RJ & Cohen GH (2005) Glycoprotein 
D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J 
Virol 79, 6655-6663. 
59. Nicola AV, McEvoy AM & Straus SE (2003) Roles for endocytosis and low pH in 
herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J Virol 77, 5324-5332. 
60. Tiwari V, Oh MJ, Kovacs M, Shukla SY, Valyi-Nagy T & Shukla D (2008) Role for 
nectin-1 in herpes simplex virus 1 entry and spread in human retinal pigment epithelial cells. 
FEBS J 275, 5272-5285. 
61. Spear PG, Manoj S, Yoon M, Jogger CR, Zago A & Myscofski D (2006) Different 
receptors binding to distinct interfaces on herpes simplex virus gD can trigger events leading 
to cell fusion and viral entry. Virology 344, 17-24. 
62. Satoh T, Arii J, Suenaga T, Wang J, Kogure A, Uehori J, Arase N, Shiratori I, Tanaka 
S, Kawaguchi Y, Spear PG, Lanier LL & Arase H (2008) PILRalpha is a herpes simplex 
virus-1 entry coreceptor that associates with glycoprotein B. Cell 132, 935-944. 
63. Suenaga T, Satoh T, Somboonthum P, Kawaguchi Y, Mori Y & Arase H Myelin-
associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. 
Proc Natl Acad Sci U S A 107, 866-871. 
64. Bender FC, Whitbeck JC, Lou H, Cohen GH & Eisenberg RJ (2005) Herpes simplex 
virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus 
entry. J Virol 79, 11588-11597. 
65. Arii J, Goto H, Suenaga T, Oyama M, Kozuka-Hata H, Imai T, Minowa A, Akashi H, 
Arase H, Kawaoka Y & Kawaguchi Y Non-muscle myosin IIA is a functional entry receptor 
for herpes simplex virus-1. Nature 467, 859-862. 
66. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ & Spear PG (1998) Entry of 
alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. 
Science 280, 1618-1620. 
67. Montgomery RI, Warner MS, Lum BJ & Spear PG (1996) Herpes simplex virus-1 
entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-
436. 
68. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg 
RJ, Rosenberg RD & Spear PG (1999) A novel role for 3-O-sulfated heparan sulfate in herpes 
simplex virus 1 entry. Cell 99, 13-22. 
69. O'Donnell CD, Kovacs M, Akhtar J, Valyi-Nagy T & Shukla D Expanding the role of 
3-O sulfated heparan sulfate in herpes simplex virus type-1 entry. Virology 397, 389-398. 
70. Subramanian RP & Geraghty RJ (2007) Herpes simplex virus type 1 mediates fusion 
through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. 
Proc Natl Acad Sci U S A 104, 2903-2908. 
71. Tiwari V, Clement C, Xu D, Valyi-Nagy T, Yue BY, Liu J & Shukla D (2006) Role 
for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into 
primary human corneal fibroblasts. J Virol 80, 8970-8980. 
 61 
72. Tiwari V, Clement C, Scanlan PM, Kowlessur D, Yue BY & Shukla D (2005) A role 
for herpesvirus entry mediator as the receptor for herpes simplex virus 1 entry into primary 
human trabecular meshwork cells. J Virol 79, 13173-13179. 
73. Esko JD & Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108, 
169-173. 
74. Lindahl U, Kusche-Gullberg M & Kjellen L (1998) Regulated diversity of heparan 
sulfate. J Biol Chem 273, 24979-24982. 
75. O'Donnell CD & Shukla D (2008) The Importance of Heparan Sulfate in Herpesvirus 
Infection. Virol Sin 23, 383-393. 
76. Tumova S, Woods A & Couchman JR (2000) Heparan sulfate proteoglycans on the 
cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 32, 269-288. 
77. Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T & Noma T (2007) 
Differential expression of syndecan isoforms during mouse incisor amelogenesis. J Med 
Invest 54, 331-339. 
78. Schofield KP, Gallagher JT & David G (1999) Expression of proteoglycan core 
proteins in human bone marrow stroma. Biochem J 343 Pt 3, 663-668. 
79. Beauvais DM, Burbach BJ & Rapraeger AC (2004) The syndecan-1 ectodomain 
regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol 167, 
171-181. 
80. Carey DJ (1997) Syndecans: multifunctional cell-surface co-receptors. Biochem J 327 
( Pt 1), 1-16. 
81. Lopes CC, Dietrich CP & Nader HB (2006) Specific structural features of syndecans 
and heparan sulfate chains are needed for cell signaling. Braz J Med Biol Res 39, 157-167. 
82. Deepa SS, Yamada S, Zako M, Goldberger O & Sugahara K (2004) Chondroitin 
sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial 
cells are structurally and functionally distinct and cooperate with heparan sulfate chains to 
bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic 
fibroblast growth factor. J Biol Chem 279, 37368-37376. 
83. Shworak NW, Shirakawa M, Mulligan RC & Rosenberg RD (1994) Characterization 
of ryudocan glycosaminoglycan acceptor sites. J Biol Chem 269, 21204-21214. 
84. Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B & 
Gallay PA (2007) Cell-free human immunodeficiency virus type 1 transcytosis through 
primary genital epithelial cells. J Virol 81, 395-405. 
85. Cheshenko N, Liu W, Satlin LM & Herold BC (2007) Multiple receptor interactions 
trigger release of membrane and intracellular calcium stores critical for herpes simplex virus 
entry. Mol Biol Cell 18, 3119-3130. 
86. Ethell IM, Irie F, Kalo MS, Couchman JR, Pasquale EB & Yamaguchi Y (2001) 
EphB/syndecan-2 signaling in dendritic spine morphogenesis. Neuron 31, 1001-1013. 
87. Shimabukuro Y, Ichikawa T, Terashima Y, Iwayama T, Oohara H, Kajikawa T, 
Kobayashi R, Terashima H, Takedachi M, Terakura M, Hashikawa T, Yamada S & 
Murakami S (2008) Basic fibroblast growth factor regulates expression of heparan sulfate in 
human periodontal ligament cells. Matrix Biol 27, 232-241. 
88. Su G, Blaine SA, Qiao D & Friedl A (2007) Shedding of syndecan-1 by stromal 
fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem 
282, 14906-14915. 
 62 
89. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM & Cormane RH (1983) 
Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. 
Arch Dermatol Res 275, 181-189. 
90. Terui T, Ozawa M & Tagami H (2000) Role of neutrophils in induction of acute 
inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated 
inflammation-boosting loop. Exp Dermatol 9, 1-10. 
91. Johnson-Huang LM, Lowes MA & Krueger JG Putting together the psoriasis puzzle: 
an update on developing targeted therapies. Dis Model Mech 5, 423-433. 
92. Nestle FO, Kaplan DH & Barker J (2009) Psoriasis. N Engl J Med 361, 496-509. 
93. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F & Muhn CY (2007) Psoriasis 
of the nail: anatomy, pathology, clinical presentation, and a review of the literature on 
therapy. J Am Acad Dermatol 57, 1-27. 
94. Bowcock AM & Cookson WO (2004) The genetics of psoriasis, psoriatic arthritis and 
atopic dermatitis. Hum Mol Genet 13 Spec No 1, R43-55. 
95. Landells I, MacCallum C & Khraishi M (2008) The role of the dermatologist in 
identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett 13, 4-7. 
96. Griffiths CE & Barker JN (2007) Pathogenesis and clinical features of psoriasis. 
Lancet 370, 263-271. 
97. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen 
M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM & Krueger JG (2005) 
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in 
psoriasis vulgaris. Proc Natl Acad Sci U S A 102, 2075-2080. 
98. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, 
Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, 
Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM & Krueger JG (2005) 
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in 
psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 102, 19057-
19062. 
99. Baker BS, Garioch JJ, Hardman C, Powles A & Fry L (1997) Induction of cutaneous 
lymphocyte-associated antigen expression by group A streptococcal antigens in psoriasis. 
Arch Dermatol Res 289, 671-676. 
100. Peters BP, Weissman FG & Gill MA (2000) Pathophysiology and treatment of 
psoriasis. Am J Health Syst Pharm 57, 645-659; quiz 660-641. 
101. Barisic-Drusko V & Rucevic I (2004) Trigger factors in childhood psoriasis and 
vitiligo. Coll Antropol 28, 277-285. 
102. Seyhan M, Coskun BK, Saglam H, Ozcan H & Karincaoglu Y (2006) Psoriasis in 
childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int 48, 
525-530. 
103. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG & Valdimarsson 
H (2003) Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a 
prospective study. Br J Dermatol 149, 530-534. 
104. Horiuchi N, Aiba S, Ozawa H, Sugawara S, Rikiishi H, Kumagai K & Tagami H 
(1998) Peripheral blood lymphocytes from psoriatic patients are hyporesponsive to beta-
streptococcal superantigens. Br J Dermatol 138, 229-235. 
105. Langley RG, Krueger GG & Griffiths CE (2005) Psoriasis: epidemiology, clinical 
features, and quality of life. Ann Rheum Dis 64 Suppl 2, ii18-23; discussion ii24-15. 
 63 
106. Bernstein CN, Wajda A & Blanchard JF (2005) The clustering of other chronic 
inflammatory diseases in inflammatory bowel disease: a population-based study. 
Gastroenterology 129, 827-836. 
107. Rehal B, Modjtahedi BS, Morse LS, Schwab IR & Maibach HI Ocular psoriasis. J Am 
Acad Dermatol 65, 1202-1212. 
108. Sommer DM, Jenisch S, Suchan M, Christophers E & Weichenthal M (2006) 
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. 
Arch Dermatol Res 298, 321-328. 
109. Gupta MA & Gupta AK (1998) Depression and suicidal ideation in dermatology 
patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139, 846-
850. 
110. Gupta MA, Gupta AK & Watteel GN (1996) Cigarette smoking in men may be a risk 
factor for increased severity of psoriasis of the extremities. Br J Dermatol 135, 859-860. 
111. Gupta MA, Schork NJ, Gupta AK & Ellis CN (1993) Alcohol intake and treatment 
responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 28, 730-732. 
112. Farkas A & Kemeny L Psoriasis and alcohol: is cutaneous ethanol one of the missing 
links? Br J Dermatol 162, 711-716. 
113. Morris A, Rogers M, Fischer G & Williams K (2001) Childhood psoriasis: a clinical 
review of 1262 cases. Pediatr Dermatol 18, 188-198. 
114. Elder JT, Nair RP & Voorhees JJ (1994) Epidemiology and the genetics of psoriasis. J 
Invest Dermatol 102, 24S-27S. 
115. Farber EM, Bright RD & Nall ML (1968) Psoriasis. A questionnaire survey of 2,144 
patients. Arch Dermatol 98, 248-259. 
116. Rahman P, Gladman DD, Schentag CT & Petronis A (1999) Excessive paternal 
transmission in psoriatic arthritis. Arthritis Rheum 42, 1228-1231. 
117. Zhang XJ, He PP, Wang ZX, Zhang J, Li YB, Wang HY, Wei SC, Chen SY, Xu SJ, 
Jin L, Yang S & Huang W (2002) Evidence for a major psoriasis susceptibility locus at 
6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. J 
Invest Dermatol 119, 1361-1366. 
118. Pasic A, Lipozencic J, Ceovic R & Kostovic K (2009) The genetics of psoriasis--
selected novelties in 2008. Acta Dermatovenerol Croat 17, 176-181. 
119. Alshobaili HA, Shahzad M, Al-Marshood A, Khalil A, Settin A & Barrimah I Genetic 
background of psoriasis. Int J Health Sci (Qassim) 4, 23-29. 
120. Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Belouchi M, 
Fournier H, Reinhard C, Ding J, Li Y, Tejasvi T, Gudjonsson J, Stoll SW, Voorhees JJ, 
Lambert S, Weidinger S, Eberlein B, Kunz M, Rahman P, Gladman DD, Gieger C, 
Wichmann HE, Karlsen TH, Mayr G, Albrecht M, Kabelitz D, Mrowietz U, Abecasis GR, 
Elder JT, Schreiber S, Weichenthal M & Franke A Genome-wide association study identifies 
a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 42, 991-995. 
121. Capon F, Bijlmakers MJ, Wolf N, Quaranta M, Huffmeier U, Allen M, Timms K, 
Abkevich V, Gutin A, Smith R, Warren RB, Young HS, Worthington J, Burden AD, Griffiths 
CE, Hayday A, Nestle FO, Reis A, Lanchbury J, Barker JN & Trembath RC (2008) 
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet 
17, 1938-1945. 
122. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, 
Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, 
Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG & Begovich AB (2007) A 
 64 
large-scale genetic association study confirms IL12B and leads to the identification of IL23R 
as psoriasis-risk genes. Am J Hum Genet 80, 273-290. 
123. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, 
Apel M, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Lascorz J, Bohm B, Traupe H, 
Lohmann J, Gieger C, Wichmann HE, Herold C, Steffens M, Klareskog L, Wienker TF, 
Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A & Reis A 
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and 
psoriasis. Nat Genet 42, 996-999. 
124. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, 
Pullinger CR, Kane JP, Saccone S, Worthington J, Bruce I, Kwok PY, Menter A, Krueger J, 
Barton A, Saccone NL & Bowcock AM (2008) A genome-wide association study of psoriasis 
and psoriatic arthritis identifies new disease loci. PLoS Genet 4, e1000041. 
125. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, 
Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi 
SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, 
Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM & Abecasis GR (2009) 
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat 
Genet 41, 199-204. 
126. Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, Barton A, Band G, 
Bellenguez C, Bergboer JG, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Cork MJ, 
Corvin A, Deloukas P, Dilthey A, Duncanson A, Edkins S, Estivill X, Fitzgerald O, Freeman 
C, Giardina E, Gray E, Hofer A, Huffmeier U, Hunt SE, Irvine AD, Jankowski J, Kirby B, 
Langford C, Lascorz J, Leman J, Leslie S, Mallbris L, Markus HS, Mathew CG, McLean 
WH, McManus R, Mossner R, Moutsianas L, Naluai AT, Nestle FO, Novelli G, Onoufriadis 
A, Palmer CN, Perricone C, Pirinen M, Plomin R, Potter SC, Pujol RM, Rautanen A, Riveira-
Munoz E, Ryan AW, Salmhofer W, Samuelsson L, Sawcer SJ, Schalkwijk J, Smith CH, 
Stahle M, Su Z, Tazi-Ahnini R, Traupe H, Viswanathan AC, Warren RB, Weger W, Wolk K, 
Wood N, Worthington J, Young HS, Zeeuwen PL, Hayday A, Burden AD, Griffiths CE, Kere 
J, Reis A, McVean G, Evans DM, Brown MA, Barker JN, Peltonen L, Donnelly P & 
Trembath RC A genome-wide association study identifies new psoriasis susceptibility loci 
and an interaction between HLA-C and ERAP1. Nat Genet 42, 985-990. 
127. Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE, Li Y, Weidinger 
S, Eberlein B, Gieger C, Wichmann HE, Kunz M, Ike R, Krueger GG, Bowcock AM, 
Mrowietz U, Lim HW, Voorhees JJ, Abecasis GR, Weichenthal M, Franke A, Rahman P, 
Gladman DD & Elder JT Genome-wide association analysis identifies three psoriasis 
susceptibility loci. Nat Genet 42, 1000-1004. 
128. Sun LD, Cheng H, Wang ZX, Zhang AP, Wang PG, Xu JH, Zhu QX, Zhou HS, 
Ellinghaus E, Zhang FR, Pu XM, Yang XQ, Zhang JZ, Xu AE, Wu RN, Xu LM, Peng L, 
Helms CA, Ren YQ, Zhang C, Zhang SM, Nair RP, Wang HY, Lin GS, Stuart PE, Fan X, 
Chen G, Tejasvi T, Li P, Zhu J, Li ZM, Ge HM, Weichenthal M, Ye WZ, Shen SK, Yang BQ, 
Sun YY, Li SS, Lin Y, Jiang JH, Li CT, Chen RX, Cheng J, Jiang X, Zhang P, Song WM, 
Tang J, Zhang HQ, Sun L, Cui J, Zhang LJ, Tang B, Huang F, Qin Q, Pei XP, Zhou AM, 
Shao LM, Liu JL, Zhang FY, Du WD, Franke A, Bowcock AM, Elder JT, Liu JJ, Yang S & 
Zhang XJ Association analyses identify six new psoriasis susceptibility loci in the Chinese 
population. Nat Genet 42, 1005-1009. 
129. Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, Westphal E, Guo 
SW, Christophers E, Voorhees JJ & Elder JT (1997) Evidence for two psoriasis susceptibility 
 65 
loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. 
Hum Mol Genet 6, 1349-1356. 
130. Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, Schork NJ, Kim J, 
Lim HW, Christophers E, Voorhees JJ & Elder JT (2000) Localization of psoriasis-
susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66, 
1833-1844. 
131. Allen MH, Ameen H, Veal C, Evans J, Ramrakha-Jones VS, Marsland AM, Burden 
AD, Griffiths CE, Trembath RC & Barker JN (2005) The major psoriasis susceptibility locus 
PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol 124, 103-106. 
132. Duffin KC, Chandran V, Gladman DD, Krueger GG, Elder JT & Rahman P (2008) 
Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 35, 
1449-1453. 
133. Sagoo GS, Cork MJ, Patel R & Tazi-Ahnini R (2004) Genome-wide studies of 
psoriasis susceptibility loci: a review. J Dermatol Sci 35, 171-179. 
134. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Catier J, Fernandez-
Vina MA & Menter A (2001) Insights into psoriasis and other inflammatory diseases from 
large-scale gene expression studies. Hum Mol Genet 10, 1793-1805. 
135. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB & Leung DY (2003) 
Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a 
gene microarray analysis. J Allergy Clin Immunol 112, 1195-1202. 
136. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, Wong WH & Bowcock AM 
(2003) Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of 
psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13, 69-78. 
137. Kulski JK, Kenworthy W, Bellgard M, Taplin R, Okamoto K, Oka A, Mabuchi T, 
Ozawa A, Tamiya G & Inoko H (2005) Gene expression profiling of Japanese psoriatic skin 
reveals an increased activity in molecular stress and immune response signals. J Mol Med 
(Berl) 83, 964-975. 
138. Quekenborn-Trinquet V, Fogel P, Aldana-Jammayrac O, Ancian P, Demarchez M, 
Rossio P, Richards HL, Kirby B, Nguyen C, Voegel JJ & Griffiths CE (2005) Gene 
expression profiles in psoriasis: analysis of impact of body site location and clinical severity. 
Br J Dermatol 152, 489-504. 
139. Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, Ghosh D, Aphale A, 
Gumucio DL, Voorhees JJ, Abecasis GR & Elder JT (2009) Global gene expression analysis 
reveals evidence for decreased lipid biosynthesis and increased innate immunity in 
uninvolved psoriatic skin. J Invest Dermatol 129, 2795-2804. 
140. Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken H, Phillip S, Haritonova 
N, Artuc M, Schweiger S, Sterry W & Foerster J (2008) PPARdelta enhances keratinocyte 
proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest 
Dermatol 128, 110-124. 
141. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ, Jr., 
Ellingsworth L, Derynck R & Voorhees JJ (1989) Overexpression of transforming growth 
factor alpha in psoriatic epidermis. Science 243, 811-814. 
142. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, Elder JT, 
Kunkel SL & Dixit VM (1991) Cellular localization of interleukin-8 and its inducer, tumor 
necrosis factor-alpha in psoriasis. Am J Pathol 138, 129-140. 
 66 
143. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B & 
Dvorak HF (1994) Overexpression of vascular permeability factor/vascular endothelial 
growth factor and its receptors in psoriasis. J Exp Med 180, 1141-1146. 
144. Nonomura K, Yamanishi K, Yasuno H, Nara K & Hirose S (1994) Up-regulation of 
elafin/SKALP gene expression in psoriatic epidermis. J Invest Dermatol 103, 88-91. 
145. Van de Kerkhof PC, Gerritsen MJ & de Jong EM (1996) Transition from symptomless 
to lesional psoriatic skin. Clin Exp Dermatol 21, 325-329. 
146. Collins LJ & Penny D (2009) The RNA infrastructure: dark matter of the eukaryotic 
cell? Trends Genet 25, 120-128. 
147. Szell M, Bata-Csorgo Z & Kemeny L (2008) The enigmatic world of mRNA-like 
ncRNAs: their role in human evolution and in human diseases. Semin Cancer Biol 18, 141-
148. 
148. Szegedi K, Goblos A, Bacsa S, Antal M, Nemeth IB, Bata-Csorgo Z, Kemeny L, 
Dobozy A & Szell M Expression and Functional Studies on the Noncoding RNA, PRINS. Int 
J Mol Sci 14, 205-225. 
149. Bell S, Degitz K, Quirling M, Jilg N, Page S & Brand K (2003) Involvement of NF-
kappaB signalling in skin physiology and disease. Cell Signal 15, 1-7. 
150. Mercurio F, Young DB & Manning AM (2000) Detection and purification of a 
multiprotein kinase complex from mammalian cells. IKK signalsome. Methods Mol Biol 99, 
109-125. 
151. Seitz CS, Lin Q, Deng H & Khavari PA (1998) Alterations in NF-kappaB function in 
transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl 
Acad Sci U S A 95, 2307-2312. 
152. Van Antwerp DJ, Martin SJ, Kafri T, Green DR & Verma IM (1996) Suppression of 
TNF-alpha-induced apoptosis by NF-kappaB. Science 274, 787-789. 
153. Sur I, Ulvmar M & Toftgard R (2008) The two-faced NF-kappaB in the skin. Int Rev 
Immunol 27, 205-223. 
154. Ghosh S & Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl, 
S81-96. 
155. Desai P & Person S (1998) Incorporation of the green fluorescent protein into the 
herpes simplex virus type 1 capsid. J Virol 72, 7563-7568. 
156. Shukla D, Rowe CL, Dong Y, Racaniello VR & Spear PG (1999) The murine 
homolog (Mph) of human herpesvirus entry protein B (HveB) mediates entry of pseudorabies 
virus but not herpes simplex virus types 1 and 2. J Virol 73, 4493-4497. 
157. Akhtar J, Tiwari V, Oh MJ, Kovacs M, Jani A, Kovacs SK, Valyi-Nagy T & Shukla D 
(2008) HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry 
into human conjunctival epithelium. Invest Ophthalmol Vis Sci 49, 4026-4035. 
158. Burbach BJ, Friedl A, Mundhenke C & Rapraeger AC (2003) Syndecan-1 
accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biol 22, 
163-177. 
159. Kis K, Bodai L, Polyanka H, Eder K, Pivarcsi A, Duda E, Soos G, Bata-Csorgo Z & 
Kemeny L (2006) Budesonide, but not tacrolimus, affects the immune functions of normal 
human keratinocytes. Int Immunopharmacol 6, 358-368. 
160. Magalhaes A, Marcos NT, Carvalho AS, David L, Figueiredo C, Bastos J, David G & 
Reis CA (2009) Helicobacter pylori cag pathogenicity island-positive strains induce 
syndecan-4 expression in gastric epithelial cells. FEMS Immunol Med Microbiol 56, 223-232. 
 67 
161. Lewis DA, Hengeltraub SF, Gao FC, Leivant MA & Spandau DF (2006) Aberrant NF-
kappaB activity in HaCaT cells alters their response to UVB signaling. J Invest Dermatol 126, 
1885-1892. 
162. Takizawa H (1998) Airway epithelial cells as regulators of airway inflammation 
(Review). Int J Mol Med 1, 367-378. 
163. Laberge S & El Bassam S (2004) Cytokines, structural cells of the lungs and airway 
inflammation. Paediatr Respir Rev 5 Suppl A, S41-45. 
164. Barker JN, Mitra RS, Griffiths CE, Dixit VM & Nickoloff BJ (1991) Keratinocytes as 
initiators of inflammation. Lancet 337, 211-214. 
165. Trybala E, Liljeqvist JA, Svennerholm B & Bergstrom T (2000) Herpes simplex virus 
types 1 and 2 differ in their interaction with heparan sulfate. J Virol 74, 9106-9114. 
166. Menozzi FD, Reddy VM, Cayet D, Raze D, Debrie AS, Dehouck MP, Cecchelli R & 
Locht C (2006) Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin 
(HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight 
junctions. Microbes Infect 8, 1-9. 
167. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, 
Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE & Baumert TF (2003) 
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan 
sulfate. J Biol Chem 278, 41003-41012. 
168. Giroglou T, Florin L, Schafer F, Streeck RE & Sapp M (2001) Human papillomavirus 
infection requires cell surface heparan sulfate. J Virol 75, 1565-1570. 
169. Shukla SY, Singh YK & Shukla D (2009) Role of nectin-1, HVEM, and PILR-alpha 
in HSV-2 entry into human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 50, 
2878-2887. 
170. Fuki IV, Meyer ME & Williams KJ (2000) Transmembrane and cytoplasmic domains 
of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane 
rafts. Biochem J 351 Pt 3, 607-612. 
171. Rapraeger A, Jalkanen M, Endo E, Koda J & Bernfield M (1985) The cell surface 
proteoglycan from mouse mammary epithelial cells bears chondroitin sulfate and heparan 
sulfate glycosaminoglycans. J Biol Chem 260, 11046-11052. 
172. Couchman JR (2003) Syndecans: proteoglycan regulators of cell-surface 
microdomains? Nat Rev Mol Cell Biol 4, 926-937. 
173. Grootjans JJ, Zimmermann P, Reekmans G, Smets A, Degeest G, Durr J & David G 
(1997) Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. Proc Natl Acad Sci 
U S A 94, 13683-13688. 
174. Chaturvedi V, Qin JZ, Denning MF, Choubey D, Diaz MO & Nickoloff BJ (2001) 
Abnormal NF-kappaB signaling pathway with enhanced susceptibility to apoptosis in 
immortalized keratinocytes. J Dermatol Sci 26, 67-78. 
175. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K & Akira S 
(1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to 
lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162, 3749-3752. 
176. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M & Aderem 
A (1999) The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates 
between pathogens. Nature 401, 811-815. 
177. Pivarcsi A, Szell M, Kemeny L, Dobozy A & Bata-Csorgo Z (2001) Serum factors 
regulate the expression of the proliferation-related genes alpha5 integrin and keratin 1, but not 
keratin 10, in HaCaT keratinocytes. Arch Dermatol Res 293, 206-213. 
 68 
178. Olaru F & Jensen LE Chemokine expression by human keratinocyte cell lines after 
activation of Toll-like receptors. Exp Dermatol 19, e314-316. 
179. Maas-Szabowski N, Starker A & Fusenig NE (2003) Epidermal tissue regeneration 
and stromal interaction in HaCaT cells is initiated by TGF-alpha. J Cell Sci 116, 2937-2948. 
180. Szegedi K, Sonkoly E, Nagy N, Nemeth IB, Bata-Csorgo Z, Kemeny L, Dobozy A & 
Szell M The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the 
non-coding RNA, PRINS. Exp Dermatol 19, 269-278. 
181. Cheriyath V, Leaman DW & Borden EC Emerging roles of FAM14 family members 
(G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer. J Interferon Cytokine Res 
31, 173-181. 
182. Szell M, Bata-Csorgo Z, Koreck A, Pivarcsi A, Polyanka H, Szeg C, Gaal M, Dobozy 
A & Kemeny L (2004) Proliferating keratinocytes are putative sources of the psoriasis 
susceptibility-related EDA+ (extra domain A of fibronectin) oncofetal fibronectin. J Invest 
Dermatol 123, 537-546. 
183. Bata-Csorgo Z, Hammerberg C, Voorhees JJ & Cooper KD (1995) Kinetics and 
regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. 
Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation 
among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 95, 317-327. 
 
 
 69 
Acknowledgements 
 
 
I would like to thank Marta Szell, DSc and Deepak Shukla, PhD for their support and 
professional supervision of my scientific work. 
I wish to thank the Rosztoczy Foundation and Professor Lajos Kemény for providing me the 
excellent opportunity to work at the Department of Ophthalmology and Visual Sciences at 
University of Illinois at Chicago and at the Department of Dermatology and Allergology at 
University of Szeged.  
I am very grateful to Tibor Valyi-Nagy, MD, PhD continues support and encouragement. 
Thank to Myung-Jin Oh, Ghadah Karasneh, Dr. Bernadett Kormos, Dr. Attila Bebes, Gábor 
Tax, Dr. Gergı Groma, Dr. Kornélia Szabó, Andrea Tanácsné Bajkán and Éva Dósa Rácz and 
to all colleagues who provided me a lot of help in my work. 
My special thanks to my husband for his support and continuous encouragement.  
Publication of Bari et al. is supported by the European Union and co-funded by the European 
Social Fund through the TÁMOP-4.2.2.A-11/1/KONV-2012-0035 European Union Grant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
 
 
 
 
 
 
 
  Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
 
 
 
 
 
 
 
 
 
 
 
 
 
I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. 
